

Longitudinal analyses reveal immunological misfiring in

Nature

584, 463-469

DOI: [10.1038/s41586-020-2588-y](https://doi.org/10.1038/s41586-020-2588-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Global Epidemiology. <i>BMJ: British Medical Journal</i> , 1962, 1, 332-332.	2.4	0
2	Distinguishable Immunologic Characteristics of COVID-19 Patients with Comorbid Type 2 Diabetes Compared with Nondiabetic Individuals. <i>Mediators of Inflammation</i> , 2020, 2020, 1-10.	1.4	21
3	A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. <i>International Journal of Infectious Diseases</i> , 2020, 101, 342-345.	1.5	46
4	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	204
5	On the genetics and immunopathogenesis of COVID-19. <i>Clinical Immunology</i> , 2020, 220, 108591.	1.4	32
6	IFN- γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. <i>Virus Research</i> , 2020, 289, 198171.	1.1	134
7	Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. <i>Nature Genetics</i> , 2020, 52, 1283-1293.	9.4	217
8	As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention. <i>Frontiers in Immunology</i> , 2020, 11, 591897.	2.2	14
9	Virology, transmission, and pathogenesis of SARS-CoV-2. <i>BMJ, The</i> , 2020, 371, m3862.	3.0	515
10	The Effects of Immune System Modulation on Prion Disease Susceptibility and Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7299.	1.8	12
11	Sex differences in immune responses that underlie COVID-19 disease outcomes. <i>Nature</i> , 2020, 588, 315-320.	13.7	1,035
12	Before Virus, After Virus: A Reckoning. <i>Cell</i> , 2020, 183, 308-314.	13.5	6
13	The Good, The Bad and The Ugly: A Mathematical Model Investigates the Differing Outcomes Among COVID-19 Patients. <i>Journal of the Indian Institute of Science</i> , 2020, 100, 673-681.	0.9	11
14	Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2020, 52, 2654-2658.	0.3	11
15	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. <i>Cell</i> , 2020, 183, 1354-1366.e13.	13.5	184
16	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> , 2020, 183, 996-1012.e19.	13.5	1,494
17	Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?. <i>European Journal of Pharmacology</i> , 2020, 889, 173629.	1.7	23
18	Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. <i>Immunity</i> , 2020, 53, 487-495.	6.6	127

#	ARTICLE	IF	CITATIONS
19	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516.	7.0	563
20	Integrative Network Analysis of Predicted miRNA-Targets Regulating Expression of Immune Response Genes in Bovine Coronavirus Infection. <i>Frontiers in Genetics</i> , 2020, 11, 584392.	1.1	8
21	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a ⁺ . <i>Molecular Therapy</i> , 2020, 28, 2691-2702.	3.7	35
22	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
23	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 606456.	2.2	98
24	Preserving immune homeostasis with A20. <i>Advances in Immunology</i> , 2020, 148, 1-48.	1.1	7
25	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. <i>Immunity</i> , 2020, 53, 1296-1314.e9.	6.6	278
26	Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. <i>Scientific Reports</i> , 2020, 10, 20533.	1.6	66
27	Cytokine Storm. <i>New England Journal of Medicine</i> , 2020, 383, 2255-2273.	13.9	1,911
28	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. <i>Science Advances</i> , 2020, 6, .	4.7	204
29	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020, 182, 1419-1440.e23.	13.5	1,162
30	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science</i> , 2020, 369, 1210-1220.	6.0	947
31	The type I interferon response in COVID-19: implications for treatment. <i>Nature Reviews Immunology</i> , 2020, 20, 585-586.	10.6	317
32	COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 256.	7.1	152
33	The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. <i>Nature Medicine</i> , 2020, 26, 1819-1824.	15.2	32
34	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. <i>Cell</i> , 2020, 183, 1479-1495.e20.	13.5	449
35	SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. <i>Blood</i> , 2020, 136, 2905-2917.	0.6	108
36	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. <i>Science Advances</i> , 2020, 6, .	4.7	128

#	ARTICLE	IF	CITATIONS
37	A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. <i>Frontiers in Immunology</i> , 2020, 11, 572635.	2.2	11
38	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. <i>Open Biology</i> , 2020, 10, 200160.	1.5	232
39	An ace model for SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	4
40	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. <i>Clinical Infectious Diseases</i> , 2021, 73, e2932-e2942.	2.9	143
41	Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. <i>European Respiratory Journal</i> , 2020, 56, 2003006.	3.1	172
42	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	46
43	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	198
44	Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis. <i>Frontiers in Immunology</i> , 2020, 11, 574862.	2.2	71
45	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025.	3.3	279
46	Monocyte activation in systemic Covid-19 infection: Assay and rationale. <i>EBioMedicine</i> , 2020, 59, 102964.	2.7	80
47	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
48	Dietary Regulation of Immunity. <i>Immunity</i> , 2020, 53, 510-523.	6.6	64
49	Suboptimal SARS-CoV-2-specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24384-24391.	3.3	168
50	Natural killer cell immunotypes related to COVID-19 disease severity. <i>Science Immunology</i> , 2020, 5, .	5.6	344
51	Unraveling the Immune Response in Severe COVID-19. <i>Journal of Clinical Immunology</i> , 2020, 40, 958-959.	2.0	8
52	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. <i>Hepatology</i> , 2021, 74, 1088-1100.	3.6	58
53	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697.	1.6	65
54	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 602183.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Dysregulated Interferon Response Underlying Severe COVID-19. <i>Viruses</i> , 2020, 12, 1433.	1.5	64
56	COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12004.	5.5	43
57	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. <i>Med</i> , 2020, 1, 90-102.	2.2	87
58	B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020, 11, 611004.	2.2	101
59	Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. <i>Frontiers in Physiology</i> , 2020, 11, 587013.	1.3	12
60	â€œNETs and EETs, a Whole Web of Messâ€. <i>Microorganisms</i> , 2020, 8, 1925.	1.6	16
61	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. <i>Pathogens</i> , 2020, 9, 1027.	1.2	20
62	Immunology of COVID-19. <i>Environmental Microbiology</i> , 2020, 22, 4895-4908.	1.8	21
63	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. <i>Cell</i> , 2020, 183, 1496-1507.e16.	13.5	182
64	Highways to hell: Mechanism-based management of cytokine storm syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 949-959.	1.5	39
65	T-cell dysregulation in COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 204-210.	1.0	50
66	Preliminary predictive criteria for COVID-19 cytokine storm. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 88-95.	0.5	165
67	SARS-CoV-2-specific virulence factors in COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 1343-1350.	2.5	60
68	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	4.1	444
69	Risk factors for severe and critically ill COVID-19 patients: A review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 428-455.	2.7	904
70	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
71	Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12998.	1.3	201
72	Neutrophils and COVID-19: The road so far. <i>International Immunopharmacology</i> , 2021, 90, 107233.	1.7	130

#	ARTICLE	IF	CITATIONS
73	Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. <i>EBioMedicine</i> , 2021, 63, 103154.	2.7	143
74	Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110982.	2.5	65
75	Synergism of TNF- α and IFN- γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. <i>Cell</i> , 2021, 184, 149-168.e17.	13.5	923
76	Thrombocytopeny and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. <i>Nature Reviews Cardiology</i> , 2021, 18, 194-209.	6.1	304
77	COVID-19 cytokine storm: what is in a name?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 3-5.	0.5	17
78	A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 18-29.	1.3	16
79	COVID19- clinical presentation and therapeutic considerations. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 125-131.	1.0	26
80	Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.. <i>Autoimmunity Reviews</i> , 2021, 20, 102726.	2.5	18
81	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
82	Biomarkers for the clinical development of antiviral therapies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 19-32.	0.7	2
83	Paired Nasopharyngeal and Deep Lung Testing for Severe Acute Respiratory Syndrome Coronavirus-2 Reveals a Viral Gradient in Critically Ill Patients. <i>Chest</i> , 2021, 159, 1387-1390.	0.4	13
84	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
85	T cell immunobiology and cytokine storm of COVID-19. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12989.	1.3	77
86	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 607583.	2.2	12
88	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. <i>PLoS Pathogens</i> , 2021, 17, e1009287.	2.1	22
89	Sex differences in immune responses. <i>Science</i> , 2021, 371, 347-348.	6.0	123
90	Stem cells part of the innate and adaptive immune systems as a therapeutic for Covid-19. <i>Communicative and Integrative Biology</i> , 2021, 14, 186-198.	0.6	6
91	A Missing Link: Engagements of Dendritic Cells in the Pathogenesis of SARS-CoV-2 Infections. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1118.	1.8	14

#	ARTICLE	IF	CITATIONS
92	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. International Journal of Environmental Research and Public Health, 2021, 18, 904.	1.2	32
93	The role of CD4 ⁺ FoxP3 ⁺ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. International Journal of Biological Sciences, 2021, 17, 1507-1520.	2.6	55
94	Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. PLoS Pathogens, 2021, 17, e1009292.	2.1	76
95	Comprehensive Meta-Analysis of COVID-19 Global Metabolomics Datasets. Metabolites, 2021, 11, 44.	1.3	72
96	Immune determinants of COVID-19 disease presentation and severity. Nature Medicine, 2021, 27, 28-33.	15.2	490
97	Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity?. Journal of Clinical Investigation, 2021, 131, .	3.9	16
98	Control and prevention of infectious diseases from a One Health perspective. Genetics and Molecular Biology, 2021, 44, e20200256.	0.6	38
100	Systemic Inflammatory Index Is a Novel Predictor of Intubation Requirement and Mortality after SARS-CoV-2 Infection. Pathogens, 2021, 10, 58.	1.2	29
102	COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?. Contributions To Nephrology, 2021, 199, 1-15.	1.1	3
103	lluminating the immunopathology of SARS-CoV-2. Cytometry Part B - Clinical Cytometry, 2021, 100, 33-41.	0.7	11
104	MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Reports, 2021, 34, 108628.	2.9	287
105	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
106	Dexamethasone Ameliorates Severe Pneumonia But Slightly Enhances Viral Replication in Lung of SARS-CoV-2-Infected Syrian Hamster. SSRN Electronic Journal, 0, , .	0.4	0
107	The "false-positive" conundrum: IgA reference level overestimates the seroprevalence of antibodies to SARS-CoV-2. Journal of Global Health, 2021, 11, 05001.	1.2	2
108	Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100048.	1.7	6
109	Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal of Clinical Immunology, 2021, 41, 738-747.	2.0	18
110	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annual Review of Microbiology, 2021, 75, 19-47.	2.9	52
112	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. Frontiers in Immunology, 2020, 11, 599736.	2.2	16

#	ARTICLE	IF	CITATIONS
115	COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-18.	1.4	215
116	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
117	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines' Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S54-S60.	0.1	9
118	Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis. <i>Heliyon</i> , 2021, 7, e05877.	1.4	5
121	Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial. <i>Journal of Infectious Diseases</i> , 2021, 223, 1339-1344.	1.9	2
122	Are all cytokine storms the same?. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 887-892.	2.0	2
124	A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling. <i>Journal of Biological Chemistry</i> , 2021, 296, 100630.	1.6	12
125	An overview of SARS-COV-2 related hepatic injury. <i>Hepatology Forum</i> , 2021, , .	0.3	3
126	Genetic Variation, Diet, Inflammation, and the Risk for COVID-19. <i>Lifestyle Genomics</i> , 2021, 14, 37-42.	0.6	20
127	SARS-CoV-2: Outline, Prevention, and Decontamination. <i>Pathogens</i> , 2021, 10, 114.	1.2	12
128	Roles of Type I and III Interferons in COVID-19. <i>Yonsei Medical Journal</i> , 2021, 62, 381.	0.9	17
129	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. <i>Genome Medicine</i> , 2021, 13, 7.	3.6	193
130	Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. <i>Cellular and Molecular Immunology</i> , 2021, 18, 539-555.	4.8	179
131	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848.	1.9	176
132	Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1285.	1.7	45
133	CSF1R defines the mononuclear phagocyte system lineage in human blood in health and COVID-19. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	10
134	type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS. Wellcome Open Research, 2021, 6, 38.	0.9	29
135	Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community. <i>Scientific Reports</i> , 2021, 11, 4243.	1.6	19

#	ARTICLE	IF	CITATIONS
136	SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. <i>Journal of Medical Virology</i> , 2021, 93, 3047-3054.	2.5	12
137	Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients. <i>Cells</i> , 2021, 10, 506.	1.8	20
138	Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. <i>Viruses</i> , 2021, 13, 271.	1.5	30
139	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	7.7	93
140	Microbiota Modulation of the Gut-Lung Axis in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 635471.	2.2	138
141	Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. <i>Scientific Reports</i> , 2021, 11, 3461.	1.6	30
142	ÂNew COVID-19 Strain (SARS-Cov-2 VUI 202012/01): Lurking Challenge. <i>Cross Current International Journal of Medical and Biosciences</i> , 2021, 3, 18-24.	0.1	0
146	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. <i>Journal of NeuroVirology</i> , 2021, 27, 191-195.	1.0	95
147	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	1.8	14
148	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 624483.	1.8	110
149	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609204.	1.8	22
151	COVID-19 and immunity: <i>quo vadis</i>?. <i>International Immunology</i> , 2021, 33, 507-513.	1.8	5
154	Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. <i>European Respiratory Journal</i> , 2021, 58, 2002724.	3.1	34
155	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
156	Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19. <i>Trends in Food Science and Technology</i> , 2021, 108, 223-235.	7.8	95
157	Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. <i>Thorax</i> , 2021, 76, 907-919.	2.7	90
160	Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 2941.	1.6	102
161	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30

#	ARTICLE	IF	CITATIONS
163	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. <i>Critical Care Medicine</i> , 2021, 49, 598-622.	0.4	49
164	The Heterogeneous Landscape and Early Evolution of Pathogen-Associated CpG Dinucleotides in SARS-CoV-2. <i>Molecular Biology and Evolution</i> , 2021, 38, 2428-2445.	3.5	15
166	Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 ⁺ T Cell Recognition <i>In Vivo</i> . <i>Journal of Virology</i> , 2021, 95, .	1.5	20
167	The cytokine storm and thyroid hormone changes in COVID-19. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 891-904.	1.8	63
168	Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 269-283.	8.2	223
170	Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study. <i>Virologica Sinica</i> , 2021, 36, 859-868.	1.2	13
172	P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thromboinflammation. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 241-252.	1.7	17
173	The Immunopathology of COVID-19 and the Cannabis Paradigm. <i>Frontiers in Immunology</i> , 2021, 12, 631233.	2.2	25
174	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 625881.	2.2	30
175	Interleukin-6 Trajectory and Secondary Infections in Mechanically Ventilated Patients With Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Treated With Interleukin-6 Receptor Blocker. , 2021, 3, e0343.		8
176	The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	32
178	Metabolic Alterations in SARS-CoV-2 Infection and Its Implication in Kidney Dysfunction. <i>Frontiers in Physiology</i> , 2021, 12, 624698.	1.3	33
179	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
180	The intersection of COVID-19 and autoimmunity: What is our current understanding?. <i>Pathogens and Immunity</i> , 2021, 6, 31-54.	1.4	20
182	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 63-85.	2.7	40
183	Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 650331.	2.2	72
184	Interleukin-6 blocking agents for treating COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013881.	1.5	106
185	The Role of Immunogenetics in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2636.	1.8	21

#	ARTICLE	IF	CITATIONS
186	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. <i>Nature</i> , 2021, 593, 418-423.	13.7	151
187	Neutrophils in respiratory viral infections. <i>Mucosal Immunology</i> , 2021, 14, 815-827.	2.7	69
188	COVID-19 vasculitis and novel vasculitis mimics. <i>Lancet Rheumatology, The</i> , 2021, 3, e224-e233.	2.2	125
189	Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	97
190	High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3987-4002.	2.4	13
192	Longitudinal multi-omics transition associated with fatality in critically ill COVID-19 patients. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 13.	0.9	9
195	SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. <i>Clinical Immunology</i> , 2021, 224, 108662.	1.4	20
197	Considering Personalized Interferon Beta Therapy for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	9
198	Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 829-840.	2.3	70
199	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
200	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108863.	2.9	92
201	Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 602130.	2.2	21
202	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, .	2.8	58
203	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. <i>Fundamental Research</i> , 2021, 1, 124-130.	1.6	5
204	Aging and Interferons: Impacts on Inflammation and Viral Disease Outcomes. <i>Cells</i> , 2021, 10, 708.	1.8	32
205	Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology. <i>Frontiers in Pharmacology</i> , 2021, 12, 622554.	1.6	27
206	Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 320, R250-R257.	0.9	21
207	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115

#	ARTICLE	IF	CITATIONS
208	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
210	Serological Testing for COVID-19 Disease: Moving the Field of Serological Surveillance Forward. <i>Journal of applied laboratory medicine</i> , The, 2021, 6, 584-587.	0.6	4
211	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , 2021, 12, 1660.	5.8	132
212	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	161
213	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 632814.	2.2	62
214	Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1801-1814.	1.8	67
215	Neutrophils in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 652470.	2.2	206
216	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. , 2021, , .		3
220	Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections With <i>Streptococcus pneumoniae</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 643326.	1.8	39
221	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. <i>Viruses</i> , 2021, 13, 516.	1.5	5
226	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	1.0	172
227	Seroconversion stages COVID19 into distinct pathophysiological states. <i>ELife</i> , 2021, 10, .	2.8	40
229	A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer: If early cytokine score results are available and to compare with existing severity scores and CT scan observations. <i>International Journal of Infectious Diseases</i> , 2021, 104, 752.	1.5	0
230	SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. <i>Cell Death Discovery</i> , 2021, 7, 43.	2.0	194
231	Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. <i>Seminars in Immunopathology</i> , 2021, 43, 383-392.	2.8	36
233	COVID-19 convalescent plasma composition and immunological effects in severe patients. <i>Journal of Autoimmunity</i> , 2021, 118, 102598.	3.0	92
234	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. <i>Immunity</i> , 2021, 54, 557-570.e5.	6.6	153
236	Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. <i>Nature Communications</i> , 2021, 12, 1618.	5.8	168

#	ARTICLE	IF	CITATIONS
237	Researchers Seek Answers for Millions With Long COVID-19. <i>IEEE Pulse</i> , 2021, 12, 17-21.	0.1	0
240	Beyond Unconventional: What Do We Really Know about Group 2 Innate Lymphoid Cells?. <i>Journal of Immunology</i> , 2021, 206, 1409-1417.	0.4	8
244	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	259
245	The spatial landscape of lung pathology during COVID-19 progression. <i>Nature</i> , 2021, 593, 564-569.	13.7	249
247	Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution. <i>EBioMedicine</i> , 2021, 65, 103262.	2.7	21
248	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325
249	Cellular Immune Response to COVID-19 and Potential Immune Modulators. <i>Frontiers in Immunology</i> , 2021, 12, 646333.	2.2	47
251	Highlights from a year in a pandemic. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	4
253	Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. <i>Vaccines</i> , 2021, 9, 436.	2.1	152
254	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. <i>Infection</i> , 2021, 49, 703-714.	2.3	27
255	IFN- γ and TNF- α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. <i>Genome Medicine</i> , 2021, 13, 64.	3.6	128
260	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. <i>Critical Care</i> , 2021, 25, 140.	2.5	27
261	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. <i>Cancer Discovery</i> , 2021, 11, 1330-1335.	7.7	3
262	Complement cascade in severe forms of COVID-19: Recent advances in therapy. <i>European Journal of Immunology</i> , 2021, 51, 1652-1659.	1.6	46
263	Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. <i>Nature Genetics</i> , 2021, 53, 801-808.	9.4	188
264	Obesity and its impact on COVID-19. <i>Journal of Molecular Medicine</i> , 2021, 99, 899-915.	1.7	41
266	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. <i>Journal of Virology</i> , 2021, 95, .	1.5	121
267	Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019. <i>Frontiers in Immunology</i> , 2021, 12, 651656.	2.2	23

#	ARTICLE	IF	CITATIONS
268	Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives. <i>Current Obesity Reports</i> , 2021, 10, 214-243.	3.5	50
269	Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut. <i>Molecular Systems Biology</i> , 2021, 17, e10232.	3.2	78
270	Relationship of COVID-19 pathogenesis for periodontal medicine research. Part II: Periodontal Medicine. <i>Research, Society and Development</i> , 2021, 10, e2010513731.	0.0	0
271	From bedside to bench: regulation of host factors in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 483-494.	3.2	6
272	Inflammatory Profiles and Clinical Features of Coronavirus 2019 Survivors 3 Months After Discharge in Wuhan, China. <i>Journal of Infectious Diseases</i> , 2021, 224, 1473-1488.	1.9	30
273	Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. <i>Thorax</i> , 2021, 76, 1010-1019.	2.7	53
274	Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals. <i>Communications Biology</i> , 2021, 4, 486.	2.0	15
275	Versatile and flexible microfluidic qPCR test for high-throughput SARS-CoV-2 and cellular response detection in nasopharyngeal swab samples. <i>PLoS ONE</i> , 2021, 16, e0243333.	1.1	14
276	COVID-19 and the human innate immune system. <i>Cell</i> , 2021, 184, 1671-1692.	13.5	524
277	High dimensional cytokine panels reveal common SARS-CoV-2-related inflammation patterns across different latitudes. <i>EBioMedicine</i> , 2021, 66, 103328.	2.7	1
278	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021, 82, 58-66.	1.7	44
279	CRISPR-based functional genomics in human dendritic cells. <i>ELife</i> , 2021, 10, .	2.8	10
280	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1217-1225.	1.5	61
281	Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. <i>Cell</i> , 2021, 184, 1836-1857.e22.	13.5	167
282	Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. <i>Immunity</i> , 2021, 54, 797-814.e6.	6.6	272
283	Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. <i>ELife</i> , 2021, 10, .	2.8	106
285	The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 82-91.	3.2	81
286	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. <i>Nature Reviews Microbiology</i> , 2021, 19, 425-441.	13.6	202

#	ARTICLE	IF	CITATIONS
287	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. <i>Trends in Immunology</i> , 2021, 42, 312-322.	2.9	86
288	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. <i>Journal of Thoracic Oncology</i> , 2021, 16, 546-571.	0.5	25
290	GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice. <i>Viruses</i> , 2021, 13, 966.	1.5	21
293	Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 660019.	2.2	15
294	Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging. <i>Nature Aging</i> , 2021, 1, 535-549.	5.3	22
295	Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. <i>Nature Cell Biology</i> , 2021, 23, 538-551.	4.6	114
296	Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2021, 2, 100291.	3.3	17
297	Blood DNA methylation and COVID-19 outcomes. <i>Clinical Epigenetics</i> , 2021, 13, 118.	1.8	68
298	Infection-induced inflammation from specific inborn errors of immunity to COVID-19. <i>FEBS Journal</i> , 2021, 288, 5021-5041.	2.2	12
299	Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. <i>IScience</i> , 2021, 24, 102477.	1.9	49
300	Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection. <i>MBio</i> , 2021, 12, .	1.8	53
301	Type I and III interferon responses in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 750-760.	3.2	187
303	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. <i>Cell</i> , 2021, 184, 2618-2632.e17.	13.5	80
304	Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. <i>Immunity</i> , 2021, 54, 1083-1095.e7.	6.6	164
305	The Systemic Immune Response in COVID-19 Is Associated with a Shift to Formyl-Peptide Unresponsive Eosinophils. <i>Cells</i> , 2021, 10, 1109.	1.8	11
306	Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	11
307	Distinct phenotypes of platelet, monocyte, and neutrophil activation occur during the acute and convalescent phase of COVID-19. <i>Platelets</i> , 2021, 32, 1092-1102.	1.1	13
309	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6

#	ARTICLE	IF	CITATIONS
311	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. <i>Molecular Cancer</i> , 2021, 20, 76.	7.9	42
312	IL-6-based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1652-1661.e1.	1.5	14
314	type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS. Wellcome Open Research, 2021, 6, 38.	0.9	35
315	Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital. <i>Internal and Emergency Medicine</i> , 2022, 17, 53-64.	1.0	7
316	Immunological Subpopulations Within Critically Ill COVID-19 Patients. <i>Chest</i> , 2021, 159, 1706-1708.	0.4	1
318	COVID-19 in trauma: a propensity-matched analysis of COVID and non-COVID trauma patients. <i>European Journal of Trauma and Emergency Surgery</i> , 2021, 47, 1335-1342.	0.8	12
319	Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. <i>Cell Reports Medicine</i> , 2021, 2, 100287.	3.3	183
321	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	15.2	365
322	HGF, IL-1 β , and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2017.	1.0	34
323	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 9, e002550.		15
324	Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 657363.	2.2	34
325	Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 206, 2605-2613.	0.4	7
326	Monocytes and macrophages in severe COVID-19: friend, foe or both?. <i>Immunology and Cell Biology</i> , 2021, 99, 561-564.	1.0	11
328	Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 21-30.	1.9	15
329	Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> , 2021, 27, 1178-1186.	15.2	183
331	Organoids to Dissect Gastrointestinal Virus-Host Interactions: What Have We Learned?. <i>Viruses</i> , 2021, 13, 999.	1.5	11
333	Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. <i>Clinical Infectious Diseases</i> , 2022, 74, 254-262.	2.9	28
335	COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009402.	1.3	14

#	ARTICLE	IF	CITATIONS
338	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
340	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021, 51, 1615-1627.	1.6	49
341	Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. <i>Journal of Infectious Diseases</i> , 2021, 224, 777-782.	1.9	26
342	RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. <i>Nature Immunology</i> , 2021, 22, 820-828.	7.0	169
343	Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. <i>Cell Reports Medicine</i> , 2021, 2, 100275.	3.3	64
344	TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. <i>Nature Immunology</i> , 2021, 22, 829-838.	7.0	364
345	Combined Cardiac Risk Factors Predict COVID-19 Related Mortality and the Need for Mechanical Ventilation in Coptic Clergy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2066.	1.0	4
346	Diverse functional autoantibodies in patients with COVID-19. <i>Nature</i> , 2021, 595, 283-288.	13.7	619
348	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 684014.	2.2	37
349	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5729-5741.	2.5	37
350	Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments. <i>Viruses</i> , 2021, 13, 1141.	1.5	48
351	Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7017.	1.8	43
352	Phenome-wide and expression quantitative trait locus associations of coronavirus disease 2019 genetic risk loci. <i>IScience</i> , 2021, 24, 102550.	1.9	9
353	Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2866-2881.	2.7	59
354	Activation of NF- κ B and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 13464.	1.6	140
355	IL-13 is a driver of COVID-19 severity. <i>JCI Insight</i> , 2021, 6, .	2.3	80
356	Emerging Evidence for Pleiotropism of Eosinophils. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7075.	1.8	18
357	Cytokine signatures of end organ injury in COVID-19. <i>Scientific Reports</i> , 2021, 11, 12606.	1.6	24

#	ARTICLE	IF	CITATIONS
358	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	0.6	118
359	Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 1292.	1.6	34
360	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
361	COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021, 9, 750-765.	1.6	18
362	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. <i>Scientific Reports</i> , 2021, 11, 13308.	1.6	50
363	Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. <i>Diagnostics</i> , 2021, 11, 1091.	1.3	135
364	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	6.6	230
365	Senolytics reduce coronavirus-related mortality in old mice. <i>Science</i> , 2021, 373, .	6.0	184
366	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9
367	Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2021, 19, 272.	1.8	19
369	Alterations in T and B cell function persist in convalescent COVID-19 patients. <i>Med</i> , 2021, 2, 720-735.e4.	2.2	87
370	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	2.3	35
371	Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. <i>Nature Cell Biology</i> , 2021, 23, 620-630.	4.6	67
372	Eosinophils and Chronic Respiratory Diseases in Hospitalized COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 668074.	2.2	13
373	Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets. <i>Frontiers in Immunology</i> , 2021, 12, 680134.	2.2	54
374	Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype. <i>Frontiers in Immunology</i> , 2021, 12, 691725.	2.2	36
375	Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D. <i>Nutrients</i> , 2021, 13, 2216.	1.7	15
376	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021, 88, 52-62.	1.0	14

#	ARTICLE	IF	CITATIONS
377	Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?. International Journal of Molecular Sciences, 2021, 22, 6764.	1.8	25
378	Ketogenic diet restrains aging-induced exacerbation of coronavirus infection in mice. ELife, 2021, 10, .	2.8	37
379	Enhancing the Human Health Status Prediction: The ATHLOS Project. Applied Artificial Intelligence, 2021, 35, 834-856.	2.0	0
380	Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. Journal of Experimental Medicine, 2021, 218, .	4.2	139
381	Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19. Frontiers in Immunology, 2021, 12, 697405.	2.2	30
382	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nature Medicine, 2021, 27, 1012-1024.	15.2	109
384	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	3.7	114
385	Viral Respiratory Pathogens and Lung Injury. Clinical Microbiology Reviews, 2021, 34, .	5.7	76
386	Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients. MBio, 2021, 12, e0122921.	1.8	20
387	Traditional Chinese medicine as a tourism recovery drawcard to boost China's inbound tourism after COVID-19. Asia Pacific Journal of Marketing and Logistics, 2022, 34, 385-400.	1.8	6
388	Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study. Blood Purification, 2022, 51, 233-242.	0.9	18
390	COVID-19 and Kounis Syndrome: Deciphering Their Relationship. Balkan Medical Journal, 2021, 38, 145-149.	0.3	13
391	COVID-19: Lung-Centric Immunothrombosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 679878.	1.8	21
393	SARS-CoV-2 genomic surveillance identifies naturally occurring truncation of ORF7a that limits immune suppression. Cell Reports, 2021, 35, 109197.	2.9	65
394	Aging and respiratory viral infection: from acute morbidity to chronic sequelae. Cell and Bioscience, 2021, 11, 112.	2.1	20
396	An Impaired Inflammatory and Innate Immune Response in COVID-19. Molecules and Cells, 2021, 44, 384-391.	1.0	13
397	Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 605-613.	1.2	26
398	Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity, 2021, 54, 1186-1199.e7.	6.6	71

#	ARTICLE	IF	CITATIONS
402	Using "big data"™ to disentangle aging and COVID-19. <i>Nature Aging</i> , 2021, 1, 496-497.	5.3	2
403	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
404	Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 11462.	1.6	11
405	The Role of Th17 Response in COVID-19. <i>Cells</i> , 2021, 10, 1550.	1.8	86
408	Immunothrombosis: a COVID-19 concerto. <i>British Journal of Haematology</i> , 2021, 194, 491-493.	1.2	2
409	SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. <i>EMBO Journal</i> , 2021, 40, e107826.	3.5	144
410	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 230.	3.8	139
411	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021, 33, 419-430.	2.0	53
412	Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: prospective cohort study. <i>BMJ Open</i> , 2021, 11, e053036.	0.8	63
413	Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study. <i>PLoS ONE</i> , 2021, 16, e0254167.	1.1	41
415	Innate Immune Cytokine Profiling and Biomarker Identification for Outcome in Dengue Patients. <i>Frontiers in Immunology</i> , 2021, 12, 677874.	2.2	3
416	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	7
417	COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7481.	1.8	37
419	Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. <i>Cell Host and Microbe</i> , 2021, 29, 1052-1062.	5.1	185
420	CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. <i>IScience</i> , 2021, 24, 102711.	1.9	79
421	Kynurenic acid may underlie sex-specific immune responses to COVID-19. <i>Science Signaling</i> , 2021, 14, .	1.6	58
422	Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. <i>Nature Communications</i> , 2021, 12, 4314.	5.8	29
424	Pathogenesis of the initial stages of severe COVID-19. <i>Journal of Clinical Practice</i> , 2021, 12, 83-102.	0.2	5

#	ARTICLE	IF	CITATIONS
425	Transcriptome Analysis of Peripheral Blood Mononuclear Cells Reveals Distinct Immune Response in Asymptomatic and Re-Detectable Positive COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 716075.	2.2	13
427	COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. <i>PLoS Pathogens</i> , 2021, 17, e1009753.	2.1	61
429	SARS-CoV-2 acquisition and immune pathogenesis among school-aged learners in four diverse schools. <i>Pediatric Research</i> , 2021, 90, 1073-1080.	1.1	6
430	High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202001009.	1.3	8
431	A dossier on COVID-19 chronicle. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 45-54.	0.7	3
432	Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7540.	1.8	12
433	SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 132-150.	0.8	50
434	Generating hard-to-obtain information from easy-to-obtain information: Applications in drug discovery and clinical inference. <i>Patterns</i> , 2021, 2, 100288.	3.1	5
435	Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases. <i>Molecular Aspects of Medicine</i> , 2021, 81, 101000.	2.7	12
436	Vitamin D, infections and immunity. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 265-277.	2.6	100
437	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021, 5, 1586-1604.	2.0	7
438	The RNA sensor MDA5 detects SARS-CoV-2 infection. <i>Scientific Reports</i> , 2021, 11, 13638.	1.6	93
442	Anti-Lethal Therapy of COVID-19 for Home Health Outpatient Therapy. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 73-79.	0.1	0
443	Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. <i>Heliyon</i> , 2021, 7, e07635.	1.4	9
444	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	2.2	5
445	Coronavirus Disease 2019 in a Patient With a Systemic Autoinflammatory Syndrome due to an NLRC4 Inflammasomopathy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab362.	0.4	4
446	Monocytes and Macrophages in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 720109.	2.2	168
447	Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. <i>Immunity</i> , 2021, 54, 1578-1593.e5.	6.6	75

#	ARTICLE	IF	CITATIONS
448	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 255.	7.1	355
449	COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 1131-1138.	0.8	4
452	The prognostic value of the SOFA score in patients with COVID-19. <i>Medicine (United States)</i> , 2021, 100, e26900.	0.4	41
453	Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	108
454	Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing. <i>European Journal of Immunology</i> , 2022, 52, 109-122.	1.6	22
455	Clinical laboratory evaluation of COVID-19. <i>Clinica Chimica Acta</i> , 2021, 519, 172-182.	0.5	30
457	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723585.	2.2	11
459	SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis. <i>Journal of Immunology</i> , 2021, 207, 1591-1598.	0.4	4
460	Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	85
461	COVID-19: Inflammatory Profile. <i>Annual Review of Medicine</i> , 2022, 73, 65-80.	5.0	43
462	Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities. <i>Frontiers in Immunology</i> , 2021, 12, 601080.	2.2	7
463	Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19. <i>ELife</i> , 2021, 10, .	2.8	64
464	CIDO ontology updates and secondary analysis of host responses to COVID-19 infection based on ImmPort reports and literature. <i>Journal of Biomedical Semantics</i> , 2021, 12, 18.	0.9	9
465	Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19. <i>Journal of Immunology</i> , 2021, 207, 1229-1238.	0.4	21
467	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. <i>PLoS Biology</i> , 2021, 19, e3001373.	2.6	7
468	Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 677025.	2.2	7
469	Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. <i>Clinical and Translational Science</i> , 2021, 14, 2556-2565.	1.5	13
470	Nervous System-Systemic Crosstalk in SARS-CoV-2/COVID-19: A Unique Dyshomeostasis Syndrome. <i>Frontiers in Neuroscience</i> , 2021, 15, 727060.	1.4	11

#	ARTICLE	IF	CITATIONS
471	The "cytokine storm": molecular mechanisms and therapeutic prospects. <i>Trends in Immunology</i> , 2021, 42, 681-705.	2.9	156
473	High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1182.	0.8	10
474	Natural killer cells and unconventional T cells in COVID-19. <i>Current Opinion in Virology</i> , 2021, 49, 176-182.	2.6	28
475	Persistent human bocavirus 1 infection and tonsillar immune responses. <i>Clinical and Translational Allergy</i> , 2021, 11, e12030.	1.4	6
476	The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 115-121.	0.5	3
477	Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 589-600.	0.5	5
478	COVID-19 Disease, Women's Predominant Non-Heparin Vaccine-Induced Thrombotic Thrombocytopenia and Kounis Syndrome: A Passepourtout Cytokine Storm Interplay. <i>Biomedicines</i> , 2021, 9, 959.	1.4	14
480	Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. <i>Advances in Biological Regulation</i> , 2021, 81, 100818.	1.4	10
481	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 694-703.	10.6	210
482	SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8660.	1.8	14
483	COVID-19: Relationship and Impact on Breastfeeding? A Systematic Review. <i>Nutrients</i> , 2021, 13, 2972.	1.7	15
484	TLQP: Early-stage transportation lock-down and quarantine problem. <i>Transportation Research Part C: Emerging Technologies</i> , 2021, 129, 103218.	3.9	14
487	Type I Interferons in COVID-19 Pathogenesis. <i>Biology</i> , 2021, 10, 829.	1.3	32
489	Altered function and differentiation of age-associated B cells contribute to the female bias in lupus mice. <i>Nature Communications</i> , 2021, 12, 4813.	5.8	47
491	Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)? <i>Frontiers in Microbiology</i> , 2021, 12, 724654.	1.5	17
492	How COVID-19 has transformed my science. <i>Neuron</i> , 2021, 109, 3041-3044.	3.8	0
494	Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1024-1034.	2.5	45
495	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	5.6	20

#	ARTICLE	IF	CITATIONS
497	Longitudinal Assessment of Cytokine Expression and Plasminogen Activation in Hantavirus Cardiopulmonary Syndrome Reveals Immune Regulatory Dysfunction in End-Stage Disease. <i>Viruses</i> , 2021, 13, 1597.	1.5	4
498	May mesenchymal stem cell transplantation be a solution for COVID-19 induced cytokine storm?. <i>World Journal of Transplantation</i> , 2021, 11, 344-355.	0.6	1
499	Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0256226.	1.1	34
500	SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19. <i>ELife</i> , 2021, 10, .	2.8	44
501	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023.	2.2	28
502	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
503	Host ADP-ribosylation and the SARS-CoV-2 macrodomain. <i>Biochemical Society Transactions</i> , 2021, 49, 1711-1721.	1.6	16
504	Peptides of <i>H. sapiens</i> and <i>P. falciparum</i> that are predicted to bind strongly to HLA-A*24:02 and homologous to a SARS-CoV-2 peptide. <i>Acta Tropica</i> , 2021, 221, 106013.	0.9	5
505	To zinc or not to zinc for COVID-19 prophylaxis or treatment?. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	4
506	Data-Driven Mathematical Modeling and Dynamical Analysis for SARS-CoV-2 Coinfection with Bacteria. <i>International Journal of Bifurcation and Chaos in Applied Sciences and Engineering</i> , 2021, 31, 2150163.	0.7	6
507	SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. <i>Glycoconjugate Journal</i> , 2021, 38, 611-623.	1.4	17
510	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
513	Analysis of SARS-CoV-2 haplotypes and genomic sequences during 2020 in Victoria, Australia, in the context of putative deficits in innate immune deaminase anti-viral responses. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13100.	1.3	3
515	Perioperative use of intra-articular steroids during the COVID-19 pandemic. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, , 1.	0.6	0
516	Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. <i>Immunity</i> , 2021, 54, 2650-2669.e14.	6.6	145
517	Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. <i>Viruses</i> , 2021, 13, 1839.	1.5	21
518	Biomarkers of Post-COVID Depression. <i>Journal of Clinical Medicine</i> , 2021, 10, 4142.	1.0	52
519	Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. <i>Science Translational Medicine</i> , 2021, 13, eabh2624.	5.8	155

#	ARTICLE	IF	CITATIONS
521	Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. <i>Cell</i> , 2021, 184, 4713-4733.e22.	13.5	206
522	The interferon landscape along the respiratory tract impacts the severity of COVID-19. <i>Cell</i> , 2021, 184, 4953-4968.e16.	13.5	165
523	Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000872.	1.2	25
524	Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. <i>Cell Reports</i> , 2021, 37, 109798.	2.9	28
525	What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1114-1128.	2.7	6
526	Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus. <i>Current Microbiology</i> , 2021, 78, 3813-3828.	1.0	4
527	From Infection to Immunity: Understanding the Response to SARS-CoV2 Through In-Silico Modeling. <i>Frontiers in Immunology</i> , 2021, 12, 646972.	2.2	35
529	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. <i>Nature Immunology</i> , 2021, 22, 1428-1439.	7.0	110
530	Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. <i>Molecules</i> , 2021, 26, 5803.	1.7	13
531	Recognition of Long-COVID-19 Patients in a Canadian Tertiary Hospital Setting: A Retrospective Analysis of Their Clinical and Laboratory Characteristics. <i>Pathogens</i> , 2021, 10, 1246.	1.2	15
532	Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury. <i>Journal of Hepatology</i> , 2021, 75, 503-505.	1.8	5
533	The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9548.	1.8	56
534	Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids. <i>Frontiers in Medicine</i> , 2021, 8, 718641.	1.2	4
535	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	2.1	39
536	A multiscale multicellular spatiotemporal model of local influenza infection and immune response. <i>Journal of Theoretical Biology</i> , 2022, 532, 110918.	0.8	7
538	Immune Responses against SARS-CoV-2—Questions and Experiences. <i>Biomedicines</i> , 2021, 9, 1342.	1.4	10
540	Identifying Risk Factors for Secondary Infection Post-SARS-CoV-2 Infection in Patients With Severe and Critical COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 715023.	2.2	9
541	Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months After Discharge. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4485-4501.	1.6	22

#	ARTICLE	IF	CITATIONS
542	Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 700921.	2.2	26
543	Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. <i>Vaccines</i> , 2021, 9, 1002.	2.1	16
544	Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 342.	7.1	22
546	Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 29-34.	2.4	34
547	Hypercoagulation and myocardial injury as risk factors for mortality in patients with COVID-19 pneumonia. <i>American Journal of Emergency Medicine</i> , 2021, 47, 313-314.	0.7	2
548	COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City. <i>Clinical Immunology</i> , 2021, 230, 108803.	1.4	3
550	Interação COVID-19/tuberculose: como a persistência de uma doença milenar impacta na gravidade de uma pandemia emergente. <i>Research, Society and Development</i> , 2021, 10, e305101119754.	0.0	1
551	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	52
552	High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease. <i>Access Microbiology</i> , 2021, 3, 000259.	0.2	13
553	The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1879.	1.5	16
554	Reply to: A finding of sex similarities rather than differences in COVID-19 outcomes. <i>Nature</i> , 2021, 597, E10-E11.	13.7	4
555	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	4.8	131
556	Multimiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2313-2324.	4.8	31
557	SARS-CoV-2, COVID-19 and the aging immune system. <i>Nature Aging</i> , 2021, 1, 769-782.	5.3	208
558	Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. <i>Cell Reports</i> , 2021, 37, 109773.	2.9	58
559	Therapeutic potential of melatonin and melatonergic drugs on K18 ^{hACE2} mice infected with SARS-CoV-2. <i>Journal of Pineal Research</i> , 2022, 72, e12772.	3.4	20
560	Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study. <i>Environment International</i> , 2021, 154, 106564.	4.8	70
561	High-value laboratory testing for hospitalized COVID-19 patients: a review. <i>Future Virology</i> , 2021, 16, 691-705.	0.9	11

#	ARTICLE	IF	CITATIONS
562	Distinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4651-4667.	1.6	24
564	IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant. <i>Frontiers in Immunology</i> , 2021, 12, 737406.	2.2	18
567	Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 211, 106412.	2.6	14
569	Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?. <i>Current Opinion in Virology</i> , 2021, 50, 119-127.	2.6	32
570	Redox modulation of vitagenes via plant polyphenols and vitamin D: Novel insights for chemoprevention and therapeutic interventions based on organoid technology. <i>Mechanisms of Ageing and Development</i> , 2021, 199, 111551.	2.2	18
571	Cutaneous Manifestations of COVID-19 in the Inpatient Setting. <i>Dermatologic Clinics</i> , 2021, 39, 521-532.	1.0	12
572	A novel hypothesis for COVID-19 pathogenesis: Retinol depletion and retinoid signaling disorder. <i>Cellular Signalling</i> , 2021, 87, 110121.	1.7	23
573	SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: An epidemiological and immunological perspective. <i>Environment International</i> , 2021, 156, 106695.	4.8	17
574	Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients. <i>Japanese Dental Science Review</i> , 2021, 57, 111-122.	2.0	24
575	Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 100, 108125.	1.7	40
576	Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients. <i>Immunology Letters</i> , 2021, 240, 1-8.	1.1	26
577	COVID-19 and the role of stem cells. <i>Regenerative Therapy</i> , 2021, 18, 334-338.	1.4	4
578	Differences in Highly Pathogenic H5N6 Avian Influenza Viral Pathogenicity and Inflammatory Response in Chickens and Ducks. <i>Frontiers in Microbiology</i> , 2021, 12, 593202.	1.5	6
579	Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19. <i>Journal of Infectious Diseases</i> , 2021, 224, 565-574.	1.9	48
580	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	14
581	Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic. <i>Journal of Biological Rhythms</i> , 2021, 36, 23-34.	1.4	28
582	No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. <i>Scientific Reports</i> , 2021, 11, 413.	1.6	156
583	Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 603961.	1.2	49

#	ARTICLE	IF	CITATIONS
584	Hamsters as a Model of Severe Acute Respiratory Syndrome Coronavirus-2. <i>Comparative Medicine</i> , 2021, 71, 398-410.	0.4	13
585	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. <i>Stem Cells Translational Medicine</i> , 2021, 10, 660-673.	1.6	281
586	Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 443-450.	1.4	3
591	SARS-CoV-2 Infection of Airway Epithelial Cells. <i>Immune Network</i> , 2021, 21, e3.	1.6	43
592	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
593	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	59
595	Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	146
596	Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. <i>Reviews in Medical Virology</i> , 2021, 31, 1-13.	3.9	82
597	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
598	Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. <i>Journal of Infection and Public Health</i> , 2020, 13, 1652-1663.	1.9	47
599	COVID-19 poses a riddle for the immune system. <i>Nature</i> , 2020, 584, 345-346.	13.7	29
600	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 299.	7.1	232
601	Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 294.	7.1	62
602	Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. <i>Bioscience Reports</i> , 2020, 40, .	1.1	29
603	Therapeutics for COVID-19: established and in development. <i>Microbiology Australia</i> , 2020, 41, 217.	0.1	2
604	Changes of peripheral lymphocyte subset in patients with SARS-CoV-2 infection during the whole course of disease. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 553-559.	1.0	3
605	Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	583
606	Frequent neurocognitive deficits after recovery from mild COVID-19. <i>Brain Communications</i> , 2020, 2, fcaa205.	1.5	236

#	ARTICLE	IF	CITATIONS
607	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 2021, 8, ofaa574.	0.4	41
608	T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology, 2021, 2, iqaa007.	1.2	19
609	The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. Current Opinion in HIV and AIDS, 2021, 16, 36-47.	1.5	6
658	Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. Journal of Immunology Research, 2020, 2020, 1-21.	0.9	6
659	Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. Journal of Clinical Investigation, 2020, 130, 6204-6213.	3.9	59
660	Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
661	SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. F1000Research, 2020, 9, 992.	0.8	10
662	Why the Patient-Made Term 'Long Covid' is needed. Wellcome Open Research, 0, 5, 224.	0.9	83
663	Disentangling the dynamical underpinnings of differences in SARS-CoV-2 pathology using within-host ecological models. PLoS Pathogens, 2020, 16, e1009105.	2.1	14
664	The Dermatological Manifestations in the Coronavirus Infection COVID-19. Russian Archives of Internal Medicine, 2020, 10, 422-429.	0.0	11
666	Synergic Viral-Bacterial Co-Infection in Catalase-Deficient COVID-19 Patients Causes Suppressed Innate Immunity and Lung Damages Due to Detrimental Elevation of Hydrogen Peroxide Concentration. SSRN Electronic Journal, 0, , .	0.4	5
667	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	1.3	56
668	Coronavirus Receptors as Immune Modulators. Journal of Immunology, 2021, 206, 923-929.	0.4	13
669	Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. American Journal of Tropical Medicine and Hygiene, 2020, 103, 2412-2418.	0.6	60
670	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
671	Integrated miRNA/Cytokine/Chemokine Profiling Reveals Severity-Associated Step Changes and Principal Correlates of Fatality in COVID-19. SSRN Electronic Journal, 0, , .	0.4	1
672	Endothelial cells are not productively infected by SARS-CoV-2. Clinical and Translational Immunology, 2021, 10, e1350.	1.7	88
673	COVID-19-associated livedo and purpura: clinical and histopathological findings. European Journal of Dermatology, 2021, 31, 568-570.	0.3	0

#	ARTICLE	IF	CITATIONS
674	The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 1109-1124.	0.2	9
675	ADAR Editing in Viruses: An Evolutionary Force to Reckon with. <i>Genome Biology and Evolution</i> , 2021, 13, .	1.1	23
676	Label-Free Cell Viability Assay and Enrichment of Cryopreserved Cells Using Microfluidic Cytometry and On-Demand Sorting. <i>Advanced Materials Technologies</i> , 2022, 7, 2100906.	3.0	11
678	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	2.8	28
679	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	5.6	37
680	T cell immunity to SARS-CoV-2. <i>Seminars in Immunology</i> , 2021, 55, 101505.	2.7	55
681	Differential roles of interferons in innate responses to mucosal viral infections. <i>Trends in Immunology</i> , 2021, 42, 1009-1023.	2.9	39
683	Cytokine signature and COVID-19 prediction models in the two waves of pandemics. <i>Scientific Reports</i> , 2021, 11, 20793.	1.6	41
684	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.	2.2	10
685	Diabetes, Heart Failure, and COVID-19: An Update. <i>Frontiers in Physiology</i> , 2021, 12, 706185.	1.3	7
687	Quality of Life (QoL) Is Reduced in Those with Severe COVID-19 Disease, Post-Acute Sequelae of COVID-19, and Hospitalization in United States Adults from Northern Colorado. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11048.	1.2	27
688	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 138-148.	1.6	33
689	Impaired function and delayed regeneration of dendritic cells in COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009742.	2.1	52
690	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
691	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , 2022, 14, eabj7521.	5.8	71
692	Rapid Detection and Inhibition of SARS-CoV-2 Spike Mutation-Mediated Microthrombosis. <i>Advanced Science</i> , 2021, 8, e2103266.	5.6	11
693	Basophils and Mast Cells in COVID-19 Pathogenesis. <i>Cells</i> , 2021, 10, 2754.	1.8	40
694	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11

#	ARTICLE	IF	CITATIONS
695	PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2. <i>Heliyon</i> , 2021, 7, e08124.	1.4	13
696	Obesity Correlates With Pronounced Aberrant Innate Immune Responses in Hospitalized Aged COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 760288.	2.2	9
697	Clash of the titans: interferons and SARS-CoV-2. <i>Trends in Immunology</i> , 2021, 42, 1069-1072.	2.9	10
698	Immunometabolic Dysregulation at the Intersection of Obesity and COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 732913.	2.2	16
699	SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. <i>Nature Immunology</i> , 2021, 22, 1452-1464.	7.0	37
701	SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. <i>Journal of Virology</i> , 2022, 96, JVI0151121.	1.5	58
702	COVID19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms. <i>Molecular Systems Biology</i> , 2021, 17, e10387.	3.2	53
703	CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. <i>Molecular Medicine</i> , 2021, 27, 129.	1.9	41
704	Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements. <i>Frontiers in Immunology</i> , 2021, 12, 769059.	2.2	16
705	Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. <i>Science Translational Medicine</i> , 2021, 13, eabi7428.	5.8	84
706	Zinc-dependent histone deacetylases drive neutrophil extracellular trap formation and potentiate local and systemic inflammation. <i>IScience</i> , 2021, 24, 103256.	1.9	26
707	Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1472-1475.	0.6	4
708	Off balance: Interferons in COVID-19 lung infections. <i>EBioMedicine</i> , 2021, 73, 103642.	2.7	31
709	Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation. <i>EBioMedicine</i> , 2021, 73, 103622.	2.7	44
710	Role of myeloid-derived suppressor cells in viral respiratory infections; Hints for discovering therapeutic targets for COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112346.	2.5	27
711	The triumvirate of NF- κ B, inflammation and cytokine storm in COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108255.	1.7	55
712	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112282.	2.5	10
714	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	138

#	ARTICLE	IF	CITATIONS
715	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1 β , Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	1.6	14
716	Immune interventions in COVID-19: a matter of time?. <i>Mucosal Immunology</i> , 2022, 15, 198-210.	2.7	14
717	Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2022, 225, 374-384.	1.9	7
719	The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 697622.	2.2	10
720	Distinct Roles of Type I and Type III Interferons during a Native Murine β 2 Coronavirus Lung Infection. <i>Journal of Virology</i> , 2022, 96, JV0124121.	1.5	10
721	Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model. <i>Frontiers in Immunology</i> , 2021, 12, 754127.	2.2	10
722	Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults. <i>Nature Aging</i> , 2021, 1, 1038-1052.	5.3	10
723	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
724	Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>PLoS Pathogens</i> , 2021, 17, e1010025.	2.1	5
727	Metabolic and inflammatory health in SARS-CoV-2 and the potential role for habitual exercise in reducing disease severity. <i>Inflammation Research</i> , 2021, , 1.	1.6	3
729	COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 134-142.	2.0	34
737	Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations. <i>Frontiers in Immunology</i> , 2020, 11, 562038.	2.2	0
740	MicroRNAs based regulation of cytokine regulating immune expressed genes and their transcription factors in COVID-19. <i>Meta Gene</i> , 2022, 31, 100990.	0.3	17
741	Recurrent bilateral idiopathic anterior uveitis with vitritis post Coronavirus Disease 2019 infection. <i>Indian Journal of Rheumatology</i> , 2021, 16, 460.	0.2	6
742	Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
743	SARS-CoV-2 Infection Dynamics in Lungs of African Green Monkeys. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
744	Neutrophil-Dependent Immunity During Pulmonary Infections and Inflammations. <i>Frontiers in Immunology</i> , 2021, 12, 689866.	2.2	16
745	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 36-46.	1.0	11

#	ARTICLE	IF	CITATIONS
746	The association between real-time reverse transcriptase polymerase chain reaction cycle threshold values, symptoms and disease severity among COVID-19 patients in the community: a retrospective cohort study. <i>Infectious Diseases</i> , 2022, 54, 205-212.	1.4	3
747	Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 382.	7.1	53
748	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. <i>EBioMedicine</i> , 2021, 73, 103637.	2.7	19
749	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
750	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9
751	A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels. <i>Frontiers in Immunology</i> , 2021, 12, 771609.	2.2	20
752	Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. <i>Seminars in Immunology</i> , 2021, 55, 101522.	2.7	12
754	Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA. <i>International Journal of Emergency Medicine</i> , 2021, 14, 68.	0.6	2
756	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. <i>Journal of Leukocyte Biology</i> , 2021, 110, 1225-1239.	1.5	4
767	Inflammation in COVID-19: from pathogenesis to treatment. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 831-844.	0.5	6
768	Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes. <i>Theranostics</i> , 2022, 12, 290-306.	4.6	11
769	T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. <i>Transplant Immunology</i> , 2022, 70, 101495.	0.6	58
770	Analysis of transcriptomic data sets supports the role of IL-6 in NETosis and immunothrombosis in severe COVID-19. <i>BMC Genomic Data</i> , 2021, 22, 49.	0.7	13
771	Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses “are we our own worst enemy?”. <i>Nature Reviews Immunology</i> , 2022, 22, 47-56.	10.6	118
772	NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. <i>Microbes and Infection</i> , 2022, 24, 104913.	1.0	30
773	Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome. <i>Scientific Reports</i> , 2021, 11, 22958.	1.6	47
774	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
775	Identification of a therapeutic interfering particle “A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. <i>Cell</i> , 2021, 184, 6022-6036.e18.	13.5	36

#	ARTICLE	IF	CITATIONS
776	Severity of SARS-CoV-2 infection is linked to double-negative (CD27 ^{hi} IgD ^{hi}) B cell subset numbers. <i>Inflammation Research</i> , 2022, 71, 131-140.	1.6	16
777	Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2. <i>Journal of Personalized Medicine</i> , 2021, 11, 1253.	1.1	3
778	Microfluidic Systems to Study Neutrophil Forward and Reverse Migration. <i>Frontiers in Immunology</i> , 2021, 12, 781535.	2.2	5
779	Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. <i>Frontiers in Immunology</i> , 2021, 12, 733921.	2.2	17
780	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	46
782	Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. <i>Frontiers in Immunology</i> , 2021, 12, 778913.	2.2	5
783	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. <i>Current HIV/AIDS Reports</i> , 2022, 19, 5-16.	1.1	9
784	An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. <i>Viruses</i> , 2021, 13, 2302.	1.5	32
785	How Immunosenescence and Inflammaging May Contribute to Hyperinflammatory Syndrome in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12539.	1.8	24
786	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
787	Complexity of immune responses in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101545.	2.7	10
788	Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients. <i>PLoS Computational Biology</i> , 2021, 17, e1009587.	1.5	11
789	High Frequencies of Functional Virus-Specific CD4 ⁺ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders. <i>Frontiers in Immunology</i> , 2021, 12, 748881.	2.2	11
790	Innate Immune Training with Bacterial Extracts Enhances Lung Macrophage Recruitment to Protect from Betacoronavirus Infection. <i>Journal of Innate Immunity</i> , 2022, 14, 293-305.	1.8	12
792	Immunological and Preventive Effects of Hochuekkito and Kakkonto Against Coronavirus Disease in Healthcare Workers: A Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 766402.	1.6	3
793	A case report describing the immune response of an infant with congenital heart disease and severe COVID-19. <i>Communications Medicine</i> , 2021, 1, .	1.9	3
794	Cerebral dysfunctions caused by sepsis during ageing. <i>Nature Reviews Immunology</i> , 2022, 22, 444-458.	10.6	55
795	Central Nervous System Effects of COVID-19 in People with HIV Infection. <i>Current HIV/AIDS Reports</i> , 2021, 18, 538-548.	1.1	7

#	ARTICLE	IF	CITATIONS
796	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	2.0	41
797	Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	25
798	A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. <i>Science Advances</i> , 2021, 7, eabj0274.	4.7	28
799	Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. <i>Nature Communications</i> , 2021, 12, 6844.	5.8	22
800	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366.	1.0	4
801	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. <i>Cancers</i> , 2021, 13, 5718.	1.7	10
802	Regulation and Function of Interferon-Lambda (IFN λ) and Its Receptor in Asthma. <i>Frontiers in Immunology</i> , 2021, 12, 731807.	2.2	14
803	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4299-4327.	1.4	0
804	Dying cells fan the flames of inflammation. <i>Science</i> , 2021, 374, 1076-1080.	6.0	117
805	COVID -19: Using high-throughput flow cytometry to dissect clinical heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, , .	1.1	4
806	Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. <i>Nature Immunology</i> , 2022, 23, 62-74.	7.0	105
807	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
808	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	5.7	64
809	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. <i>Translational Research</i> , 2022, 241, 1-12.	2.2	15
810	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. , 2021, 3, e0588.		11
811	People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden. <i>Cell Reports Medicine</i> , 2021, 2, 100476.	3.3	11
813	Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. <i>EBioMedicine</i> , 2021, 74, 103723.	2.7	26
814	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0

#	ARTICLE	IF	CITATIONS
815	Longitudinal Characterization of Circulating Neutrophils Uncovers Distinct Phenotypes Associated with Disease Severity in Hospitalized COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
816	SARS-CoV-2 Infection Generates Long-Lived Memory B Cells Against the Receptor Binding Domain of the Spike Protein. SSRN Electronic Journal, 0, , .	0.4	0
817	Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19. PLoS ONE, 2022, 17, e0260897.	1.1	7
820	Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19. IScience, 2022, 25, 103672.	1.9	25
821	HIV and Aging in the Era of ART and COVID-19: Symposium Overview. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, S3-S9.	0.9	0
822	Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients. Cytokine, 2022, 150, 155790.	1.4	12
825	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	9.4	78
826	The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature, 2022, 603, 145-151.	13.7	272
827	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	13.7	216
828	An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution. Biomedicines, 2022, 10, 296.	1.4	25
829	Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nature Communications, 2022, 13, 320.	5.8	117
830	Concurrent Infection With the Filarial Helminth Litomosoides sigmodontis Attenuates or Worsens Influenza A Virus Pathogenesis in a Stage-Dependent Manner. Frontiers in Immunology, 2021, 12, 819560.	2.2	2
831	Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nature Communications, 2022, 13, 440.	5.8	100
832	Potential Immune Indicators for Predicting the Prognosis of COVID-19 and Trauma: Similarities and Disparities. Frontiers in Immunology, 2021, 12, 785946.	2.2	7
833	Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. Journal of Hematology and Oncology, 2022, 15, 5.	6.9	30
834	Neutrophil subsets and their differential roles in viral respiratory diseases. Journal of Leukocyte Biology, 2022, 111, 1159-1173.	1.5	11
835	NET-Mediated Pathogenesis of COVID-19: The Role of NETs in Hepatic Manifestations. Journal of Health and Allied Sciences NU, 0, , .	0.1	3
836	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	5.8	71

#	ARTICLE	IF	CITATIONS
837	SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	7
838	Effect of Expanded Hemodialysis with TheraNova® in Patients with COVID-19. <i>Blood Purification</i> , 2022, 51, 857-865.	0.9	2
839	In COVID-19, NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: a nomothetic network approach. <i>Molecular Psychiatry</i> , 2022, 27, 1945-1955.	4.1	36
841	Communication Pattern Changes Along With Declined IGF1 of Immune Cells in COVID-19 Patients During Disease Progression. <i>Frontiers in Immunology</i> , 2021, 12, 729990.	2.2	3
842	Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 275-283.	1.4	5
843	SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793197.	2.2	14
844	Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. <i>Immunity</i> , 2022, 55, 542-556.e5.	6.6	96
845	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	1.6	20
846	Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505.	5.6	101
847	A sample-to-answer electrochemical biosensor system for biomarker detection. <i>Lab on A Chip</i> , 2021, 22, 100-107.	3.1	10
848	A purine metabolic checkpoint that prevents autoimmunity and autoinflammation. <i>Cell Metabolism</i> , 2022, 34, 106-124.e10.	7.2	23
849	A Journey into the Clinical Relevance of Heme Oxygenase 1 for Human Inflammatory Disease and Viral Clearance: Why Does It Matter on the COVID-19 Scene?. <i>Antioxidants</i> , 2022, 11, 276.	2.2	12
851	Respiratory viruses and eosinophilic airway inflammation. , 2022, , 204-218.		1
852	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 13-28.	1.5	5
853	COVID-19: systemic pathology and its implications for therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 386-408.	2.6	27
854	COVID, Obstructive Airway Diseases and Eosinophils. <i>Sultan Qaboos University Medical Journal</i> , 0, , .	0.3	0
855	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. <i>Nature Communications</i> , 2022, 13, 153.	5.8	45
856	Future prospects of translational and clinical eosinophil research. , 2022, , 253-262.		1

#	ARTICLE	IF	CITATIONS
857	TSLP upregulates inflammatory responses through induction of autophagy in T cells. <i>FASEB Journal</i> , 2022, 36, e22148.	0.2	3
858	Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. <i>PLoS Pathogens</i> , 2022, 18, e1010176.	2.1	20
859	Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19 convalescent individuals. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1225-1241.	1.5	5
860	Helminths and COVID-19 susceptibility, disease progression, and vaccination efficacy. <i>Trends in Parasitology</i> , 2022, 38, 277-279.	1.5	10
862	The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 816745.	2.2	9
863	Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	8
864	Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 804250.	1.6	17
865	T cell apoptosis characterizes severe Covid-19 disease. <i>Cell Death and Differentiation</i> , 2022, 29, 1486-1499.	5.0	90
867	Body composition, physical capacity, and immuno-metabolic profile in community-acquired pneumonia caused by COVID-19, influenza, and bacteria: a prospective cohort study. <i>International Journal of Obesity</i> , 2022, 46, 817-824.	1.6	9
868	Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 809937.	2.2	13
869	Eosinophilia Is Associated with Improved COVID-19 Outcomes in Inhaled Corticosteroid-Treated Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 742-750.e14.	2.0	16
870	T-Cell Repertoire Characteristics of Asymptomatic and Re-Detectable Positive COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 769442.	2.2	4
871	Association between IL-10 systemic low level and highest pain score in patients during symptomatic SARS-CoV-2 infection. <i>Pain Practice</i> , 2022, 22, 453-462.	0.9	6
872	A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. <i>Nature Communications</i> , 2022, 13, 383.	5.8	39
873	System-wide transcriptome damage and tissue identity loss in COVID-19 patients. <i>Cell Reports Medicine</i> , 2022, 3, 100522.	3.3	24
875	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 799-811.	1.9	10
876	The T cell immune response against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 186-193.	7.0	785
879	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. <i>Inflammation Research</i> , 2022, 71, 293-307.	1.6	29

#	ARTICLE	IF	CITATIONS
881	Innate immunity: the first line of defense against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 165-176.	7.0	303
882	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. <i>International Immunopharmacology</i> , 2022, 105, 108531.	1.7	1
883	COVID-19 in cancer patients. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 767-797.	0.7	11
884	The evolution of the human healthcare system and implications for understanding our responses to COVID-19. <i>Evolution, Medicine and Public Health</i> , 2022, 10, 87-107.	1.1	3
885	Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months. <i>Frontiers in Immunology</i> , 2022, 13, 817876.	2.2	15
886	Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity. <i>Frontiers in Microbiology</i> , 2022, 13, 828984.	1.5	15
887	Inflammatory Markers, Pulmonary Function, and Clinical Symptoms in Acute COVID-19 Among Non-Hospitalized Adolescents and Young Adults. <i>Frontiers in Immunology</i> , 2022, 13, 837288.	2.2	15
889	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 789882.	1.5	20
890	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals: EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
891	Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 801799.	2.2	14
893	<i>Streptococcus pneumoniae</i> colonization associates with impaired adaptive immune responses against SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	33
894	Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models. <i>Cell Death and Disease</i> , 2022, 13, 137.	2.7	9
896	RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 1225-1234.	2.3	14
897	Risk factors for Coronavirus disease-associated mucormycosis. <i>Journal of Infection</i> , 2022, 84, 383-390.	1.7	45
898	A single-cell transcriptomic landscape of the lungs of patients with COVID-19. <i>Nature Cell Biology</i> , 2021, 23, 1314-1328.	4.6	91
899	Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010211.	2.1	37
900	Regulation of early growth response-1 (Egr-1) gene expression by Stat1-independent type I interferon signaling and respiratory viruses. <i>Computational and Mathematical Biophysics</i> , 2021, 9, 289-303.	0.6	2
901	Profiling transcription factor sub-networks in type I interferon signaling and in response to SARS-CoV-2 infection. <i>Computational and Mathematical Biophysics</i> , 2021, 9, 273-288.	0.6	2

#	ARTICLE	IF	CITATIONS
902	Multiplex metal-detection based assay (MMDA) for COVID-19 diagnosis and identification of disease severity biomarkers. <i>Chemical Science</i> , 2022, 13, 3216-3226.	3.7	5
904	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10
905	Targeting ectromelia virus and TNF/NF- κ B or STAT3 signaling for effective treatment of viral pneumonia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
906	Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure. <i>Frontiers in Immunology</i> , 2022, 13, 844304.	2.2	11
907	Multiscale PHATE identifies multimodal signatures of COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 681-691.	9.4	39
908	T cell responses to SARS-CoV-2 in humans and animals. <i>Journal of Microbiology</i> , 2022, 60, 276-289.	1.3	8
909	Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. <i>Npj Digital Medicine</i> , 2022, 5, 18.	5.7	5
910	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.4	8
911	Emerging complications of COVID-19 in a subset of Indian population: a pathological review with clinico-radiological case scenarios. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2022, 53, .	0.3	0
913	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. <i>PLoS ONE</i> , 2022, 17, e0261979.	1.1	10
914	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
915	Specialized interferon action in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	56
916	Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. <i>Nature Communications</i> , 2022, 13, 915.	5.8	32
917	Immune Cells Profiles in the Different Sites of COVID-19-Affected Lung Lobes in a Single Patient. <i>Frontiers in Medicine</i> , 2022, 9, 841170.	1.2	3
918	Serum IL-28A/IFN- λ 2 is linked to disease severity of COVID-19. <i>Scientific Reports</i> , 2022, 12, 5458.	1.6	7
919	Pilot study for immunoglobulin E as a prognostic biomarker in coronavirus disease 2019. <i>Internal Medicine Journal</i> , 2022, 52, 1495-1504.	0.5	3
920	Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship. <i>World Journal of Gastroenterology</i> , 2022, 28, 1102-1112.	1.4	32
921	Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 758946.	2.2	0

#	ARTICLE	IF	CITATIONS
922	Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab. <i>Journal of Translational Medicine</i> , 2022, 20, 134.	1.8	7
924	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
926	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop—A Novel Perspective. <i>International Journal of Diabetology</i> , 2022, 3, 193-235.	0.9	6
927	Programmed cell death: the pathways to severe COVID-19?. <i>Biochemical Journal</i> , 2022, 479, 609-628.	1.7	30
928	Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 823-831.	1.4	31
929	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	2.3	23
930	The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis. <i>Journal of Infection</i> , 2022, 84, 834-872.	1.7	14
932	Count on us: T cells in SARS-CoV-2 infection and vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100562.	3.3	86
933	Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. <i>EBioMedicine</i> , 2022, 77, 103894.	2.7	12
934	Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	0
935	Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus disease-19 severity. <i>Microbiology and Immunology</i> , 2022, 66, 264-276.	0.7	5
936	The Age-Dependent Role of Th22, Tc22, and Tc17 Cells in the Severity of Pneumonia in COVID-19 Immunopathogenesis. <i>Viral Immunology</i> , 2022, 35, 318-327.	0.6	8
937	Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. <i>Cell</i> , 2022, 185, 1588-1601.e14.	13.5	137
938	Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. <i>ELife</i> , 2022, 11, .	2.8	37
939	Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients. <i>BMC Medicine</i> , 2022, 20, 129.	2.3	11
940	<i>TNFRSF1B</i> and <i>TNF</i> Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19. <i>Journal of Infectious Diseases</i> , 2022, 226, 778-787.	1.9	6
943	Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States. <i>Cells</i> , 2022, 11, 847.	1.8	27
945	Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. <i>Journal of Personalized Medicine</i> , 2022, 12, 391.	1.1	12

#	ARTICLE	IF	CITATIONS
946	STINGing type I IFN-mediated immunopathology in COVID-19. <i>Nature Immunology</i> , 2022, 23, 478-480.	7.0	15
948	LRR-protein RNH1 dampens the inflammasome activation and is associated with COVID-19 severity. <i>Life Science Alliance</i> , 2022, 5, e202101226.	1.3	7
949	The immunology and immunopathology of COVID-19. <i>Science</i> , 2022, 375, 1122-1127.	6.0	434
950	Escape and Over-Activation of Innate Immune Responses by SARS-CoV-2: Two Faces of a Coin. <i>Viruses</i> , 2022, 14, 530.	1.5	11
951	De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. <i>Nature Communications</i> , 2022, 13, 1547.	5.8	159
952	Interleukin-6-Production Is Responsible for Induction of Hepatic Synthesis of Several Chemokines as Acute-Phase Mediators in Two Animal Models: Possible Significance for Interpretation of Laboratory Changes in Severely Ill Patients. <i>Biology</i> , 2022, 11, 470.	1.3	1
953	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	13.6	404
954	Thymic Dysfunction and Atrophy in COVID-19 Disease Complicated by Inflammation, Malnutrition and Cachexia. <i>Nutrition and Health</i> , 2022, 28, 199-206.	0.6	4
955	Obesity alters pathology and treatment response in inflammatory disease. <i>Nature</i> , 2022, 604, 337-342.	13.7	93
956	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. <i>Science Immunology</i> , 2022, 7, eabo0535.	5.6	17
957	Characterization of memory T cell subsets and common β -chain cytokines in convalescent COVID-19 individuals. <i>Journal of Leukocyte Biology</i> , 2022, 112, 201-212.	1.5	15
959	Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women. <i>Journal of Immunology</i> , 2022, 208, 1857-1872.	0.4	16
960	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 545-556.	5.2	30
961	Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in the Inpatient and Outpatient Setting in a Diverse Cohort. <i>Journal of General Internal Medicine</i> , 2022, 37, 1988-1995.	1.3	61
962	Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101908.	1.6	9
963	Predicted coronavirus Nsp5 protease cleavage sites in the human proteome. <i>BMC Genomic Data</i> , 2022, 23, 25.	0.7	15
965	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394.	2.2	56
967	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. <i>Heliyon</i> , 2022, 8, e09230.	1.4	16

#	ARTICLE	IF	CITATIONS
968	Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision?. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104606.	2.9	15
969	Inflammation at the crossroads of COVID-19, cognitive deficits and depression. <i>Neuropharmacology</i> , 2022, 209, 109023.	2.0	38
970	The role of antigen-presenting cells in the pathogenesis of COVID-19. <i>Pathology Research and Practice</i> , 2022, 233, 153848.	1.0	17
971	Long-term outcomes of pediatric infections: from traditional infectious diseases to long Covid. <i>Future Microbiology</i> , 2022, 17, 551-571.	1.0	62
972	Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 341-359.	2.0	27
973	Clinical, Virological, Immunological, and Genomic Characterization of Asymptomatic and Symptomatic Cases With SARS-CoV-2 Infection in India. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 725035.	1.8	11
974	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.4	56
975	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. <i>PLoS ONE</i> , 2021, 16, e0261656.	1.1	16
976	Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar. <i>World Journal of Gastroenterology</i> , 2021, 27, 7995-8009.	1.4	2
979	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
980	Modulatory Effects of Physical Activity Levels on Immune Responses and General Clinical Functions in Adult Patients with Mild to Moderate SARS-CoV-2 Infections – A Protocol for an Observational Prospective Follow-Up Investigation: Fit-COVID-19 Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13249.	1.2	6
981	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6
982	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. <i>PLoS Pathogens</i> , 2021, 17, e1010106.	2.1	12
983	Alterations in B Cell and Follicular T-Helper Cell Subsets in Patients with Acute COVID-19 and COVID-19 Convalescents. <i>Current Issues in Molecular Biology</i> , 2022, 44, 194-205.	1.0	17
984	Mast Cell Tryptase and Implications for SARS-CoV-2 Pathogenesis. <i>BioMed</i> , 2021, 1, 136-149.	0.6	6
985	Adult Still's disease: New horizons. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 645-665.	0.2	6
987	Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 763292.	2.2	50
988	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology. <i>Cells</i> , 2022, 11, 67.	1.8	7

#	ARTICLE	IF	CITATIONS
989	A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune-epithelial interface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
990	Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6845-6853.	1.6	16
991	Identifying correlations driven by influential observations in large datasets. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
992	Epidemiology, pathophysiology, and classification of the neurological symptoms of post-COVID-19 syndrome. <i>Neurology Perspectives</i> , 2021, 1, S5-S15.	0.2	6
993	Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection. <i>PLoS Computational Biology</i> , 2021, 17, e1009735.	1.5	14
995	A humanized mouse model of chronic COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 906-920.	9.4	71
997	Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19. <i>Nature Immunology</i> , 2022, 23, 23-32.	7.0	74
999	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, 850583.	1.6	4
1000	Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19. <i>Blood Advances</i> , 2022, 6, 5085-5099.	2.5	32
1001	Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 821730.	2.2	21
1002	Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling. <i>Frontiers in Immunology</i> , 2022, 13, 865845.	2.2	7
1003	The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients. <i>Biomedicines</i> , 2022, 10, 934.	1.4	4
1004	High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity. <i>Frontiers in Immunology</i> , 2022, 13, 867716.	2.2	15
1005	Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction. <i>Vaccines</i> , 2022, 10, 614.	2.1	10
1006	Severe COVID-19-associated variants linked to chemokine receptor gene control in monocytes and macrophages. <i>Genome Biology</i> , 2022, 23, 96.	3.8	17
1007	An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells. <i>PLoS ONE</i> , 2022, 17, e0266412.	1.1	14
1013	The immune response to COVID-19: Does sex matter?. <i>Immunology</i> , 2022, 166, 429-443.	2.0	18
1014	Smallpox vaccination induces a substantial increase in commensal skin bacteria that promote pathology and influence the host response. <i>PLoS Pathogens</i> , 2022, 18, e1009854.	2.1	8

#	ARTICLE	IF	CITATIONS
1015	Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq.. Archives of Razi Institute, 2021, 76, 1255-2127.	0.4	0
1016	Association between periodontal disease and the risk of COVID-19 complications and mortality: A systematic review. Journal of International Society of Preventive and Community Dentistry, 2021, 11, 626.	0.4	6
1018	Emerging Paradigms in Type 2 Immunity. Annual Review of Immunology, 2022, 40, 443-467.	9.5	16
1019	Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2. Frontiers in Immunology, 2022, 13, 848335.	2.2	2
1020	Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development. Frontiers in Immunology, 2022, 13, 831194.	2.2	3
1021	Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. Heliyon, 2022, 8, e09302.	1.4	7
1022	Identification of serum metabolites enhancing inflammatory responses in COVID-19. Science China Life Sciences, 2022, 65, 1971-1984.	2.3	6
1023	Insights into the Role of Neutrophils and Neutrophil Extracellular Traps in Causing Cardiovascular Complications in Patients with COVID-19: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 2460.	1.0	8
1024	Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature, 2022, 606, 585-593.	13.7	276
1025	SARS-CoV-2 epitope-specific CD4 ⁺ memory T cell responses across COVID-19 disease severity and antibody durability. Science Immunology, 2022, 7, .	5.6	25
1026	Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19. Genome Medicine, 2022, 14, 46.	3.6	19
1027	Chitinase-3-like protein-1 at hospital admission predicts COVID-19 outcome: a prospective cohort study. Scientific Reports, 2022, 12, 7606.	1.6	6
1028	Immunouniverse of SARS-CoV-2. Immunological Medicine, 2022, 45, 186-224.	1.4	8
1029	HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. Frontiers in Immunology, 2022, 13, 841716.	2.2	15
1030	Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	2.2	39
1031	COVID-19 and the role of cytokines in this disease. Inflammopharmacology, 2022, 30, 789-798.	1.9	48
1032	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Frontiers in Immunology, 2022, 13, .	2.2	2
1033	ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Reports, 2022, 23, e54305.	2.0	57

#	ARTICLE	IF	CITATIONS
1034	Alterations of blood monocyte subset distribution and surface phenotype are linked to infection severity in COVID-19 inpatients. <i>European Journal of Immunology</i> , 2022, , .	1.6	4
1036	In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection. <i>Scientific Reports</i> , 2022, 12, 7237.	1.6	2
1037	A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	8
1039	A phase I trial of cyclosporine for hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	8
1040	SARS-CoV-2 induces barrier damage and inflammatory responses in the human iPSC-derived intestinal epithelium. <i>Journal of Pharmacological Sciences</i> , 2022, 149, 139-146.	1.1	14
1041	Immunological defense of CNS barriers against infections. <i>Immunity</i> , 2022, 55, 781-799.	6.6	14
1042	C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?. <i>Clinical Immunology Communications</i> , 2022, 2, 83-90.	0.5	3
1043	A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. <i>Gut Microbes</i> , 2022, 14, 2073131.	4.3	40
1044	Immune response in COVID-19: what is next?. <i>Cell Death and Differentiation</i> , 2022, 29, 1107-1122.	5.0	69
1045	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	29
1046	Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells. <i>Molecular Cell</i> , 2022, 82, 2385-2400.e9.	4.5	61
1047	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. <i>Nature Communications</i> , 2022, 13, 2774.	5.8	21
1048	ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. <i>Science Immunology</i> , 2022, 7, eabo6294.	5.6	82
1049	Single-cell RNA sequencing reveals immunological rewiring at the maternal-fetal interface following asymptomatic/mild SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 39, 110938.	2.9	18
1051	Early Recognition of Low-Risk SARS-CoV-2 Pneumonia. <i>Chest</i> , 2022, 162, 768-781.	0.4	6
1052	Nutraceutical potential of Amazonian oilseeds in modulating the immune system against COVID-19 â€“ A narrative review. <i>Journal of Functional Foods</i> , 2022, 94, 105123.	1.6	10
1053	Autophagy Hijacking in PBMC From COVID-19 Patients Results in Lymphopenia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1054	No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. <i>PLoS Biology</i> , 2022, 20, e3001506.	2.6	10

#	ARTICLE	IF	CITATIONS
1055	Bet-hedging in innate and adaptive immune systems. <i>Evolution, Medicine and Public Health</i> , 2022, 10, 256-265.	1.1	1
1056	Immune-Mediated Mechanisms of COVID-19 Neuropathology. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	9
1057	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
1058	Refractoriness of Hyperkalemia and Hyperphosphatemia in Dialysis-Dependent Acute Kidney Injury Associated with COVID-19. <i>Kidney360</i> , 0, 3, 10.34067/KID.0001632022.	0.9	1
1060	Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26.	1.3	15
1061	Activation of cGAS-STING by Lethal Malaria N67C Dictates Immunity and Mortality through Induction of CD11b ⁺ Ly6C ^{hi} Proinflammatory Monocytes. <i>Advanced Science</i> , 2022, 9, .	5.6	11
1062	Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation. <i>Nature Immunology</i> , 2022, 23, 927-939.	7.0	21
1063	Rise of the SARS-CoV-2 Variants: can proteomics be the silver bullet?. <i>Expert Review of Proteomics</i> , 2022, 19, 197-212.	1.3	2
1064	Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity. <i>Cell Systems</i> , 2022, 13, 598-614.e6.	2.9	10
1065	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, .	4.7	14
1067	Cytokine Profiling among Children with Multisystem Inflammatory Syndrome versus Simple COVID-19 Infection: A Study from Northwest Saudi Arabia. <i>Biology</i> , 2022, 11, 946.	1.3	8
1068	Clinical Characteristics and Mechanisms of Musculoskeletal Pain in Long COVID. <i>Journal of Pain Research</i> , 0, Volume 15, 1729-1748.	0.8	36
1069	Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients. <i>Immunity</i> , 2022, , .	6.6	9
1070	Cardiac Complications of COVID-19 in Low-Risk Patients. <i>Viruses</i> , 2022, 14, 1322.	1.5	9
1071	Eotaxin-1 (CCL11) in neuroinflammatory disorders and possible role in COVID-19 neurologic complications. <i>Acta Neurologica Belgica</i> , 2022, 122, 865-869.	0.5	24
1072	Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	31
1073	Time-dependent contraction of the SARS-CoV-2-specific T-cell responses in convalescent individuals. , 2022, , .		0
1074	What SARS-CoV-2 does to our brains. <i>Immunity</i> , 2022, 55, 1159-1172.	6.6	28

#	ARTICLE	IF	CITATIONS
1077	Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	15
1078	Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
1079	Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. <i>ELife</i> , 0, 11, .	2.8	31
1080	Potential role of astrocyte angiotensin converting enzyme 2 in the neural transmission of COVID-19 and a neuroinflammatory state induced by smoking and vaping. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	13
1082	SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2588-2595.	2.0	9
1083	Host-directed immunotherapy of viral and bacterial infections: past, present and future. <i>Nature Reviews Immunology</i> , 2023, 23, 121-133.	10.6	71
1084	Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. <i>IScience</i> , 2022, 25, 104612.	1.9	9
1085	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	129
1086	Uncovering the genetic links of SARS-CoV-2 infections on heart failure co-morbidity by a systems biology approach. <i>ESC Heart Failure</i> , 2022, 9, 2937-2954.	1.4	8
1087	Ketone Bodies Improve Human CD8+ Cytotoxic T-Cell Immune Response During COVID-19 Infection. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	12
1088	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	41
1089	Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. <i>Viruses</i> , 2022, 14, 1247.	1.5	24
1090	Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. <i>Cell</i> , 2022, 185, 2452-2468.e16.	13.5	237
1091	Longitudinal Analysis of Biologic Correlates of COVID-19 Resolution: Case Report. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1092	COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152047.	1.6	24
1093	Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent. <i>Cytokine</i> , 2022, 157, 155934.	1.4	19
1094	The biphasic phenomenon of cytokine storm in COVID pneumonia. <i>Annals of African Medicine</i> , 2022, 21, 168.	0.2	0
1095	Integration and Reanalysis of Four RNA-Seq Datasets Including BALF, Nasopharyngeal Swabs, Lung Biopsy, and Mouse Models Reveals Common Immune Features of COVID-19. <i>Immune Network</i> , 2022, 22, .	1.6	4

#	ARTICLE	IF	CITATIONS
1096	Purinergic System in Immune Response. <i>Biochemistry</i> , 0, , .	0.8	0
1097	The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. <i>Inflammation Research</i> , 2022, 71, 923-947.	1.6	30
1098	Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms. <i>PLoS Pathogens</i> , 2022, 18, e1010630.	2.1	14
1099	Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 369-392.	0.5	9
1101	Obesity-Mediated Immune Modulation: One Step Forward, (Th)2 Steps Back. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1102	Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. <i>Cell Reports Medicine</i> , 2022, 3, 100680.	3.3	19
1103	Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2022, 16, 799-811.	1.3	15
1104	A Game of Infection â€“ Song of Respiratory Viruses and Interferons. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	0
1105	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1106	Exposing and Overcoming Limitations of Clinical Laboratory Tests in COVID-19 by Adding Immunological Parameters; A Retrospective Cohort Analysis and Pilot Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1107	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11
1108	Was the Reduction in Seasonal Influenza Transmission during 2020 Attributable to Non-Pharmaceutical Interventions to Contain Coronavirus Disease 2019 (COVID-19) in Japan?. <i>Viruses</i> , 2022, 14, 1417.	1.5	8
1109	Lâ€™inflammasome NLRP3 dans la physiopathologie des infections virales. <i>Medecine/Sciences</i> , 2022, 38, 545-552.	0.0	3
1110	Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
1111	Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection*. <i>Immunological Reviews</i> , 2022, 309, 12-24.	2.8	39
1112	Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-Îµ and -Î³. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1113	Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. <i>PLoS ONE</i> , 2022, 17, e0269875.	1.1	0
1114	Serum gasdermin D levels are associated with the chest computed tomography findings and severity of COVID-19. <i>Respiratory Investigation</i> , 2022, 60, 750-761.	0.9	3

#	ARTICLE	IF	CITATIONS
1116	RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease. <i>Pathogens</i> , 2022, 11, 800.	1.2	3
1117	COVID-19, obesity, and immune response 2 years after the pandemic: A timeline of scientific advances. <i>Obesity Reviews</i> , 2022, 23, .	3.1	6
1118	Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	56
1119	Soluble CD137 as a potential biomarker for severe COVID-19. <i>Immunology Letters</i> , 2022, , .	1.1	1
1120	Spontaneous NLRP3 inflammasome-driven IL-1 β secretion is induced in severe COVID-19 patients and responds to anakinra treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 796-805.	1.5	26
1121	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 666-695.	0.9	22
1123	Characterisation of the blood RNA host response underpinning severity in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
1124	Innate immunity to SARS-CoV-2 infection: A review. <i>Epidemiology and Infection</i> , 0, , 1-49.	1.0	9
1125	Plasmacytoid dendritic cells during COVID-19: Ally or adversary?. <i>Cell Reports</i> , 2022, 40, 111148.	2.9	14
1126	Serum cystatin C and CRP are early predictive biomarkers for emergence of hypoxia in COVID-19. <i>American Journal of the Medical Sciences</i> , 2022, 364, 706-713.	0.4	1
1127	Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1128	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. <i>Journal of Medical Virology</i> , 2022, 94, 5128-5148.	2.5	12
1129	Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines. <i>Antiviral Research</i> , 2022, 205, 105373.	1.9	12
1130	SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	2
1131	Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases. <i>Biomedicines</i> , 2022, 10, 1750.	1.4	13
1132	Considerations for Novel COVID-19 Mucosal Vaccine Development. <i>Vaccines</i> , 2022, 10, 1173.	2.1	10
1133	Roles of RNA Sensors in Host Innate Response to Influenza Virus and Coronavirus Infections. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8285.	1.8	5
1135	Stem Cells: A Promising Therapeutic Target for COVID-19. <i>Stem Cell Discovery</i> , 2022, 12, 1-27.	0.5	1

#	ARTICLE	IF	CITATIONS
1136	Coronaviruses: Troubling Crown of the Animal Kingdom. <i>Comparative Medicine</i> , 2022, , .	0.4	3
1137	Macrophage Polarization in Viral Infectious Diseases: Confrontation with the Reality. , 0, , .		1
1138	Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1139	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
1140	Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7937.	1.8	2
1141	Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2â€“induced lung exudative vasculitis and predicts COVID-19 severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	12
1142	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1143	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	15
1144	High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19. <i>Journal of Infectious Diseases</i> , 2022, 226, 2150-2160.	1.9	12
1145	Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1816-1828.	1.4	9
1146	Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0271807.	1.1	10
1147	Inflammatory pathways in COVIDâ€“19: Mechanism and therapeutic interventions. <i>MedComm</i> , 2022, 3, .	3.1	17
1148	Regulated necrosis in COVID-19: A double-edged sword. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1149	SARS-CoV-2-reactive IFN-Î³-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1150	The Role of Inflammasomes in COVID-19: Potential Therapeutic Targets. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 406-420.	0.5	1
1151	Publication trends of research on COVID-19 and host immune response: A bibliometric analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	6
1152	Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. <i>Genome Medicine</i> , 2022, 14, .	3.6	28
1153	Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21

#	ARTICLE	IF	CITATIONS
1154	The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic. <i>Immunology</i> , 2022, 167, 287-302.	2.0	15
1155	NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic. <i>Cells</i> , 2022, 11, 2619.	1.8	4
1156	Complanatuside alleviates inflammatory cell damage induced by pro-inflammatory cytokines in skin keratinocytes. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	1
1157	Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection. <i>Biomedical Journal</i> , 2022, , .	1.4	3
1158	Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. <i>PLoS Biology</i> , 2022, 20, e3001728.	2.6	15
1159	Elevated Salivary Inflammatory Biomarkers are Associated with SARS-CoV-2 Infection Severity. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-10.	0.7	5
1160	The Low Expression of Fc-Gamma Receptor III (CD16) and High Expression of Fc-Gamma Receptor I (CD64) on Neutrophil Granulocytes Mark Severe COVID-19 Pneumonia. <i>Diagnostics</i> , 2022, 12, 2010.	1.3	1
1162	The BioFire® RP2.1 Panel Did Not Identify Concurrent Respiratory Virus Infection in Adults with Variable SARS-CoV-2 Disease Severity and Infection Duration. <i>Advances in Virology</i> , 2022, 2022, 1-6.	0.5	0
1165	Prevalence and clinical disease severity of respiratory co-infections during the COVID-19 pandemic. <i>Advances in Molecular Pathology</i> , 2022, , .	0.2	1
1166	A simple model of COVID-19 explains disease severity and the effect of treatments. <i>Scientific Reports</i> , 2022, 12, .	1.6	14
1167	The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic. <i>Pharmacological Reports</i> , 2022, 74, 1149-1165.	1.5	5
1168	Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
1170	Importancia de los Interferones en la respuesta inmune antiviral contra SARS-CoV-2. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1171	Impact of innate immunity, endothelial damage, and metabolic biomarkers on COVID-19 severity and mortality. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	2
1173	Stroke-induced changes to immune function and their relevance to increased risk of severe COVID-19 disease. , 0, , .		0
1174	Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. <i>Nature Communications</i> , 2022, 13, .	5.8	18
1175	Respiratory and systemic monocytes, dendritic cells, and myeloid-derived suppressor cells in COVID-19: Implications for disease severity. <i>Journal of Internal Medicine</i> , 2023, 293, 130-143.	2.7	16
1176	Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19. <i>Exploration of Immunology</i> , 0, , 484-509.	1.7	0

#	ARTICLE	IF	CITATIONS
1177	Increased Lung Immune Metabolic Activity in COVID-19 Survivors. <i>Clinical Nuclear Medicine</i> , 2022, 47, 1019-1025.	0.7	4
1178	SARS-CoV-2-specific T _H cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> , 2022, 55, 1764-1778.	6.6	63
1179	Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1180	Interferon Î±-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1181	Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. <i>Clinical Immunology</i> , 2022, 244, 109093.	1.4	9
1182	Repressed Ang 1 in COVID-19 Is Inversely Associated with Inflammation and Coagulation. <i>MSphere</i> , 2022, 7, .	1.3	10
1183	Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents. <i>Blood Advances</i> , 0, , .	2.5	5
1184	NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection. <i>Vaccines</i> , 2022, 10, 1307.	2.1	1
1185	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10679.	1.8	5
1186	Gastrointestinal injury in COVID-19. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 106.	0.2	1
1187	High-resolution analysis of individual spike peptide-specific CD4 ⁺ T _H cell responses in vaccine recipients and COVID-19 patients. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
1188	Dynamic Single-Cell RNA Sequencing Reveals that Intravenous BCG Vaccination Curtails SARS-CoV-2 Induced Disease Severity and Lung Inflammation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1189	Characteristics of Changes in Serum IL-6 and IL-10 Levels in Patients with COVID-19 and Their Relationship with Disease Progression: A Possible Hypothesis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1190	Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5827-5848.	2.6	15
1191	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1192	Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. <i>Nature</i> , 2022, 611, 139-147.	13.7	69
1193	Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
1194	Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. <i>Cells</i> , 2022, 11, 2686.	1.8	1

#	ARTICLE	IF	CITATIONS
1195	Relationships between plasma fatty acids in adults with mild, moderate, or severe COVID-19 and the development of post-acute sequelae. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
1196	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538.	3.9	13
1197	Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	18
1198	COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1199	Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1200	Homogeneity tests for one-way models with dependent errors under correlated groups. <i>Test</i> , 2023, 32, 163-183.	0.7	2
1201	Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19. <i>ERJ Open Research</i> , 0, , 00216-2022.	1.1	0
1202	Common human genetic variants of APOE impact murine COVID-19 mortality. <i>Nature</i> , 2022, 611, 346-351.	13.7	29
1203	Impaired immune response drives age-dependent severity of COVID-19. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	26
1204	Role of lymphoid lineage cells aberrantly expressing alarmins S100A8/A9 in determining the severity of COVID-19. <i>Genes and Genomics</i> , 0, , .	0.5	2
1205	Regulation of cGAS Activity and Downstream Signaling. <i>Cells</i> , 2022, 11, 2812.	1.8	7
1208	Formation and activity of NLRP3 inflammasome and histopathological changes in the lung of corpses with COVID-19. <i>Journal of Molecular Histology</i> , 2022, 53, 883-890.	1.0	5
1209	A shift in lung macrophage composition is associated with COVID-19 severity and recovery. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	33
1210	Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. <i>Cell Reports Medicine</i> , 2022, 3, 100779.	3.3	25
1211	Correlation between Type I Interferon Associated Factors and COVID-19 Severity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10968.	1.8	9
1213	Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. <i>Science Immunology</i> , 2022, 7, .	5.6	32
1214	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
1215	Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. <i>Communications Medicine</i> , 2022, 2, .	1.9	5

#	ARTICLE	IF	CITATIONS
1217	An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. <i>Vaccines</i> , 2022, 10, 1546.	2.1	1
1218	Elevated IL-18 predicts poor prognosis in critically ill COVID-19 patients at a Brazilian hospital in 2020-21. <i>Future Microbiology</i> , 2022, 17, 1287-1294.	1.0	4
1219	Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, .	4.7	19
1220	IFI44 is an immune evasion biomarker for SARS-CoV-2 and <i>Staphylococcus aureus</i> infection in patients with RA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1221	Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 993-1004.	1.5	14
1223	CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11338.	1.8	12
1224	The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. <i>Clinical Proteomics</i> , 2022, 19, .	1.1	3
1225	ZBP1: A Powerful Innate Immune Sensor and Double-Edged Sword in Host Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10224.	1.8	20
1226	Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1227	Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
1228	Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus. <i>Current Opinion in Immunology</i> , 2022, 78, 102252.	2.4	5
1229	Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0275217.	1.1	16
1230	Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. <i>Clinical Infectious Diseases</i> , 2023, 76, 573-581.	2.9	29
1231	Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 511-524.	1.2	3
1232	Detection of pneumococcus during hospitalization for SARS-CoV-2. <i>FEMS Microbes</i> , 2022, 3, .	0.8	2
1233	Regulation of Lysosomal Associated Membrane Protein 3 (LAMP3) in Lung Epithelial Cells by Coronaviruses (SARS-CoV-1/2) and Type I Interferon Signaling. <i>Computational and Mathematical Biophysics</i> , 2022, 10, 167-183.	0.6	0
1235	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1237	The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2-associated multisystem inflammatory syndrome in children. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	9

#	ARTICLE	IF	CITATIONS
1238	Neuroimmune Interactions in Severe COVID-19 Infection. <i>Pathogens</i> , 2022, 11, 1256.	1.2	1
1239	Adaptive immunity to SARS-CoV-2 infection: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
1240	Shared 6mer Peptides of Human and Omicron (21K and 21L) at SARS-CoV-2 Mutation Sites. <i>Antibodies</i> , 2022, 11, 68.	1.2	2
1241	A GABA-receptor agonist reduces pneumonitis severity, viral load, and death rate in SARS-CoV-2-infected mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1242	Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12260.	1.8	2
1244	Single-cell transcriptome analyses reveal distinct gene expression signatures of severe COVID-19 in the presence of clonal hematopoiesis. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1756-1765.	3.2	5
1245	COVID-associated pulmonary aspergillosis and herpes simplex virus pneumonia in a renal transplant recipient. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	1
1246	Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study. <i>ELife</i> , 0, 11, .	2.8	7
1247	Immune response induced by novel coronavirus infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	8
1250	T cell dysregulation in inflammatory diseases in ICU. <i>Intensive Care Medicine Experimental</i> , 2022, 10, .	0.9	10
1251	One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	16
1252	A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1253	Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. <i>Nature Communications</i> , 2022, 13, .	5.8	67
1254	Exploration of blood-derived coding and non-coding RNA diagnostic immunological panels for COVID-19 through a co-expressed-based machine learning procedure. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1255	Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19. <i>IScience</i> , 2022, 25, 105319.	1.9	6
1256	II. COVID-19: How Far Has the Pathogenesis been Elucidated?. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2355-2360.	0.0	0
1257	SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways. <i>JCI Insight</i> , 2022, 7, .	2.3	16
1258	Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	6

#	ARTICLE	IF	CITATIONS
1259	Association between vitamin D supplementation and COVID-19 infection and mortality. <i>Scientific Reports</i> , 2022, 12, .	1.6	37
1260	Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment. <i>Cell Reports Medicine</i> , 2022, 3, 100833.	3.3	17
1261	Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1262	Interleukin-1 β and Interleukin-10 Profiles and Ratio in Serum of COVID-19 Patients and Correlation with COVID-19 Severity: A Time Series Study. <i>International Journal of General Medicine</i> , 0, Volume 15, 8043-8054.	0.8	9
1263	Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1265	A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1266	Perturbations of immune landscape in COVID-19 associated mucormycosis. <i>Mycoses</i> , 2023, 66, 226-236.	1.8	2
1267	Death by TNF: a road to inflammation. <i>Nature Reviews Immunology</i> , 2023, 23, 289-303.	10.6	106
1268	Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1269	Combination of WFDC2, CHI3L1, and KRT19 in Plasma Defines a Clinically Useful Molecular Phenotype Associated with Prognosis in Critically Ill COVID-19 Patients. <i>Journal of Clinical Immunology</i> , 2023, 43, 286-298.	2.0	7
1270	Induction of pulmonary HLA-G expression by SARS-CoV-2 infection. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	6
1273	Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
1274	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. <i>International Immunopharmacology</i> , 2022, 113, 109428.	1.7	22
1275	Socioeconomic and race/ethnic differences in immunosenescence: Evidence from the Health and Retirement Study. <i>Brain, Behavior, and Immunity</i> , 2023, 107, 361-368.	2.0	9
1276	Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. <i>Antiviral Research</i> , 2023, 209, 105475.	1.9	12
1277	Synergism of TNF- α and IFN- γ triggers human airway epithelial cells death by apoptosis and pyroptosis. <i>Molecular Immunology</i> , 2023, 153, 160-169.	1.0	10
1278	Stimulation of interferon- β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-1 agonists. <i>IScience</i> , 2023, 26, 105742.	1.9	4
1279	Immunosenescence and inflamm-ageing in COVID-19. <i>Ageing Research Reviews</i> , 2023, 84, 101818.	5.0	18

#	ARTICLE	IF	CITATIONS
1280	Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	13
1281	Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples. <i>Nature Communications</i> , 2022, 13, .	5.8	12
1283	Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	29
1284	Efficient inference and identifiability analysis for differential equation models with random parameters. <i>PLoS Computational Biology</i> , 2022, 18, e1010734.	1.5	5
1286	Neutrophils are gatekeepers of mucosal immunity. <i>Immunological Reviews</i> , 2023, 314, 125-141.	2.8	7
1287	Preparing for the next pandemic: Simulation-based deep reinforcement learning to discover and test multimodal control of systemic inflammation using repurposed immunomodulatory agents. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1288	Defective antifungal immunity in patients with COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1289	Predictive value of specific cytokines for lethal COVID-19 outcome. <i>Russian Journal of Infection and Immunity</i> , 2022, 12, 859-868.	0.2	5
1290	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1291	Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. <i>Nature Communications</i> , 2022, 13, .	5.8	26
1292	New-onset type 1 diabetes and severe acute respiratory syndrome coronavirus 2 infection. <i>Immunology and Cell Biology</i> , 2023, 101, 191-203.	1.0	7
1293	Potential role of AIM2 inflammasome in SARS-CoV-2 infection. <i>Scandinavian Journal of Immunology</i> , 2023, 97, .	1.3	2
1294	Association between the expression of toll-like receptors, cytokines, and homeostatic chemokines in SARS-CoV-2 infection and COVID-19 severity. <i>Heliyon</i> , 2023, 9, e12653.	1.4	4
1295	Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	17
1296	Quantitative Serum NMR Spectroscopy Stratifies COVID-19 Patients and Sheds Light on Interfaces of Host Metabolism and the Immune Response with Cytokines and Clinical Parameters. <i>Metabolites</i> , 2022, 12, 1277.	1.3	10
1297	The long-term dynamics of serum antibodies against SARS-CoV-2. <i>PeerJ</i> , 0, 10, e14547.	0.9	2
1299	The signaling pathways and therapeutic potential of itaconate to alleviate inflammation and oxidative stress in inflammatory diseases. <i>Redox Biology</i> , 2022, 58, 102553.	3.9	11
1300	Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 33-50.	1.0	14

#	ARTICLE	IF	CITATIONS
1301	Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?. <i>Drugs</i> , 2023, 83, 1-36.	4.9	4
1302	The immunogenetics of COVID-19. <i>Immunogenetics</i> , 2023, 75, 309-320.	1.2	8
1303	Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	29
1304	Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?. <i>Nature Reviews Endocrinology</i> , 2023, 19, 217-231.	4.3	11
1305	Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15122.	1.8	1
1306	Correlation between 25-hydroxyvitamin D/D3 Deficiency and COVID-19 Disease Severity in Adults from Northern Colorado. <i>Nutrients</i> , 2022, 14, 5204.	1.7	3
1308	IL-7 and IL-7R in health and disease: An update through COVID times. <i>Advances in Biological Regulation</i> , 2023, 87, 100940.	1.4	3
1309	COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 141-157.	1.6	6
1310	An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. <i>Cell Host and Microbe</i> , 2023, 31, 243-259.e6.	5.1	20
1311	Correlations of Myeloperoxidase (MPO), Adenosine deaminase (ADA), C motif chemokine 22 (CCL22), Tumour necrosis factor alpha (TNF α) and Interleukin-6 (IL-6) mRNA expression in the nasopharyngeal specimens with the diagnosis and severity of SARS-CoV-2 infections. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
1312	A high CMV-specific T cell response associates with SARS-CoV-2-specific IL-17A cell production. <i>Medical Microbiology and Immunology</i> , 2023, 212, 75-91.	2.6	4
1313	Molecular modeling of C1 inhibitor as SARS-CoV-2 target identified from the immune signatures of multiple tissues: An integrated bioinformatics study. <i>Cell Biochemistry and Function</i> , 2023, 41, 112-127.	1.4	0
1315	Can Baseline IL-6 Levels Predict Long COVID in Subjects Hospitalized for SARS-CoV-2 Disease?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1731.	1.8	3
1317	Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping. <i>Health Data Science</i> , 2022, 2022, .	1.1	4
1318	PD-1 ^{high} CXCR5 ⁺ CD4 ⁺ peripheral helper T cells promote CXCR3 ⁺ plasmablasts in human acute viral infection. <i>Cell Reports</i> , 2023, 42, 111895.	2.9	9
1320	Linear epitope mapping of the humoral response against SARS-CoV-2 in two independent African cohorts. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
1321	Dynamic Changes in Circulatory Cytokines and Chemokines Levels in Mild to Severe COVID-19 Patients. <i>Indian Journal of Clinical Biochemistry</i> , 2023, 38, 212-219.	0.9	5
1322	A novel scoring system for early assessment of the risk of the COVID-19-associated mortality in hospitalized patients: COVID-19 BURDEN. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	3

#	ARTICLE	IF	CITATIONS
1323	Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1324	Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1712.	1.8	4
1325	IL-21, Inflammatory Cytokines and Hyperpolarized CD8+ T Cells Are Central Players in Lupus Immune Pathology. <i>Antioxidants</i> , 2023, 12, 181.	2.2	2
1327	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1328	Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?. <i>Antioxidants</i> , 2023, 12, 172.	2.2	6
1329	Comparison of Efficacy and Safety of Low-Dose Versus High-Dose Dexamethasone in Hospitalized COVID-19 Patients: A Meta-Analysis. <i>Cureus</i> , 2023, , .	0.2	1
1330	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
1331	Towards precision medicine: Omics approach for COVID-19. <i>Biosafety and Health</i> , 2023, 5, 78-88.	1.2	4
1332	IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
1333	Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial. <i>Current Stem Cell Research and Therapy</i> , 2024, 19, 55-62.	0.6	1
1334	Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. <i>Trends in Microbiology</i> , 2023, 31, 644-656.	3.5	7
1335	Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. <i>EClinicalMedicine</i> , 2023, 56, 101785.	3.2	9
1336	Cutting Edge: Hyperinflammatory Monocytes Expressing CD56 Abound in Severe COVID-19 Patients. <i>Journal of Immunology</i> , 2022, 209, 655-659.	0.4	4
1337	Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1338	A Counterintuitive Neutrophil-Mediated Pattern in COVID-19 Patients Revealed through Transcriptomics Analysis. <i>Viruses</i> , 2023, 15, 104.	1.5	0
1339	Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS). <i>Journal of Clinical Medicine</i> , 2023, 12, 304.	1.0	3
1340	Network pharmacology- and molecular simulation-based exploration of therapeutic targets and mechanisms of heparin for the treatment of sepsis/COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 12586-12598.	2.0	5
1341	Biomarkers in long COVID-19: A systematic review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	46

#	ARTICLE	IF	CITATIONS
1342	The role of TÂcell immunity in COVID-19. , 2023, , 129-140.		0
1343	Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients. <i>Cell Reports Medicine</i> , 2023, 4, 100935.	3.3	2
1344	Innate immune responses in COVID-19. , 2023, , 63-128.		0
1345	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. <i>Biomedicines</i> , 2023, 11, 338.	1.4	3
1346	The Role of IL-6 in Inner Ear Impairment: Evidence from 146 Recovered Patients with Omicron Infected in Tianjin, China. <i>Journal of Clinical Medicine</i> , 2023, 12, 1114.	1.0	0
1347	The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19â€”Results from a pragmatic randomized clinical trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
1348	NLRP3, the inflammasome and COVID-19 infection. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 502-507.	0.2	7
1349	A patient-centric modeling framework captures recovery from SARS-CoV-2 infection. <i>Nature Immunology</i> , 2023, 24, 349-358.	7.0	17
1350	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. <i>Oxford Open Immunology</i> , 2023, 4, .	1.2	3
1351	Innate immune recognition against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	8
1352	Review of Time Domain Electronic Medical Record Taxonomies in the Application of Machine Learning. <i>Electronics (Switzerland)</i> , 2023, 12, 554.	1.8	0
1353	Type 2 Immunity and Its Impact on COVID-19 Infection in the Airways. <i>Viruses</i> , 2023, 15, 402.	1.5	2
1354	An Innate Checkpoint Determines Immune Dysregulation and Immunopathology during Pulmonary Murine Coronavirus Infection. <i>Journal of Immunology</i> , 2023, 210, 774-785.	0.4	2
1355	Host Recovery from Respiratory Viral Infection. <i>Annual Review of Immunology</i> , 2023, 41, 277-300.	9.5	10
1356	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2
1357	Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1358	Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1359	Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. <i>Nature Immunology</i> , 2023, 24, 604-611.	7.0	36

#	ARTICLE	IF	CITATIONS
1361	Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. <i>Pharmaceuticals</i> , 2023, 16, 584.	1.7	7
1362	Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	3
1363	Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. <i>Thrombosis Research</i> , 2023, 225, 47-56.	0.8	2
1364	The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. <i>Antiviral Research</i> , 2023, 213, 105590.	1.9	4
1365	A web server for predicting and scanning of IL-5 inducing peptides using alignment-free and alignment-based method. <i>Computers in Biology and Medicine</i> , 2023, 158, 106864.	3.9	1
1368	A follow up study of cycle threshold values of SARS-CoV-2 in Hunan Province, China. <i>Infectious Disease Modelling</i> , 2023, 8, 203-211.	1.2	0
1369	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1370	Periodontitis and COVID-19: Immunological Characteristics, Related Pathways, and Association. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3012.	1.8	5
1371	The turning point of COVID-19 severity is associated with a unique circulating neutrophil gene signature. <i>Immunology</i> , 2023, 169, 323-343.	2.0	3
1372	Venous thromboembolism in viral diseases: A comprehensive literature review. <i>Health Science Reports</i> , 2023, 6, .	0.6	5
1373	Monocytic HLA-DR Expression in Immune Responses of Acute Pancreatitis and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3246.	1.8	5
1374	Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. <i>Nature Communications</i> , 2023, 14, .	5.8	16
1375	In silico study of molecular mimicry between SARS-CoV-2 and neutrophil extracellular traps composition in granulocyte-rich supernatants of patients with systemic lupus erythematosus and lupus nephritis. , 2023, , 199-274.		0
1376	The main protease of SARS-CoV-2 cleaves histone deacetylases and DCP1A, attenuating the immune defense of the interferon-stimulated genes. <i>Journal of Biological Chemistry</i> , 2023, 299, 102990.	1.6	12
1377	SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 911-921.	1.5	5
1378	CASP4/11 Contributes to NLRP3 Activation and COVID-19 Exacerbation. <i>Journal of Infectious Diseases</i> , 2023, 227, 1364-1375.	1.9	3
1379	SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. <i>IScience</i> , 2023, 26, 106175.	1.9	2
1380	Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection. <i>Frontiers in Aging</i> , 0, 4, .	1.2	5

#	ARTICLE	IF	CITATIONS
1381	The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. <i>Pathogens</i> , 2023, 12, 329.	1.2	3
1382	Association between serum ferritin level and decreased diffusion capacity 3 months after the onset of COVID-19 pneumonia. <i>PLoS ONE</i> , 2023, 18, e0281249.	1.1	2
1383	Understanding immunity: an alternative framework beyond defense and strength. <i>Biology and Philosophy</i> , 2023, 38, .	0.7	4
1384	Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220.	0.7	2
1385	The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1386	SARS-CoV-2-Induced TSLP Is Associated with Duration of Hospital Stay in COVID-19 Patients. <i>Viruses</i> , 2023, 15, 556.	1.5	4
1387	SARS-COV-2 viroporins activate the NLRP3-inflammasome by the mitochondrial permeability transition pore. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
1388	Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 3638-3658.	5.7	2
1389	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	4
1390	Persistent dysregulation of cellular immunity following COVID-19 recovery despite minimal post-COVID-19 sequelae manifestation. <i>Journal of Infection</i> , 2023, , .	1.7	1
1391	Predicting the severity of COVID-19 patients using the CD24-CSF1R index in whole blood samples. <i>Heliyon</i> , 2023, 9, e13945.	1.4	2
1393	Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants. <i>Viruses</i> , 2023, 15, 611.	1.5	1
1394	Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2023, 8, 1-10.	0.5	8
1395	Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. <i>Vaccines</i> , 2023, 11, 509.	2.1	0
1396	Innate immune cell activation causes lung fibrosis in a humanized model of long COVID. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	18
1397	Integrated Metabolic and Inflammatory Signatures Associated with Severity of, Fatality of, and Recovery from COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
1398	Bioinformatics analysis based on high-throughput sequencing data to identify hub genes related to different clinical types of COVID-19. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	2
1399	Classification of COVID-19 Patients into Clinically Relevant Subsets by a Novel Machine Learning Pipeline Using Transcriptomic Features. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4905.	1.8	4

#	ARTICLE	IF	CITATIONS
1400	The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis. <i>Journal of Infectious Diseases</i> , 2023, 227, 1245-1254.	1.9	6
1402	Neutrophil Extracellular Traps in Airway Diseases: Pathological Roles and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5034.	1.8	11
1403	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1404	The role of immune activation and antigen persistence in acute and long COVID. <i>Journal of Investigative Medicine</i> , 2023, 71, 545-562.	0.7	17
1405	Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	10
1407	Severe COVID-19 versus multisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. <i>European Respiratory Review</i> , 2023, 32, 220197.	3.0	2
1408	SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. <i>Nature Communications</i> , 2023, 14, .	5.8	9
1409	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1411	Lymphangitic Carcinomatosis of Possible Urothelial Origin. <i>Cureus</i> , 2023, , .	0.2	0
1412	Vitamin B12 attenuates leukocyte inflammatory signature in COVID-19 via methyl-dependent changes in epigenetic markings. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1414	Epigenetic immune monitoring for COVID-19 disease course prognosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1415	Circulating Adiponectin Levels Are Inversely Associated with Mortality and Respiratory Failure in Patients Hospitalized with COVID-19. <i>International Journal of Endocrinology</i> , 2023, 2023, 1-8.	0.6	4
1417	Peripheral HLA-G/ILT-2 immune checkpoint axis in acute and convalescent COVID-19 patients. <i>Human Immunology</i> , 2023, , .	1.2	1
1418	The role of interleukin 13 and the type 2 immune pathway in COVID-19: A review. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 727-732.	0.5	9
1420	SARS-CoV-2 E protein-induced THP-1 pyroptosis is reversed by Ruscogenin. <i>Biochemistry and Cell Biology</i> , 0, , .	0.9	1
1421	Patterns of cytokine and chemokine expression in peripheral blood of patients with COVID-19 associated with disease severity. <i>International Journal of Immunopathology and Pharmacology</i> , 2023, 37, 039463202311636.	1.0	3
1422	Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID. <i>European Respiratory Journal</i> , 2023, 61, 2202226.	3.1	11
1423	Serum amyloid A a potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	5

#	ARTICLE	IF	CITATIONS
1424	Post-hospitalization rehabilitation alleviates long-term immune repertoire alteration in COVID-19 convalescent patients. <i>Cell Proliferation</i> , 2023, 56, .	2.4	2
1425	Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19. <i>Journal of Clinical Immunology</i> , 2023, 43, 882-893.	2.0	1
1426	Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	11
1427	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1428	Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1429	Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19. <i>Experimental and Molecular Medicine</i> , 2023, 55, 653-664.	3.2	2
1430	Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients: A Promising Approach to Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6250.	1.8	3
1431	Sustained Perturbation of Metabolism and Metabolic Subphenotypes Are Associated With Mortality and Protein Markers of the Host Response. , 2023, 5, e0881.		4
1432	Multivariate indicators of disease severity in COVID-19. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1433	Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2023, 18, e0272826.	1.1	7
1434	Characterisation of the pro-inflammatory cytokine signature in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1435	Neutrophil Extracellular Traps and Platelet Activation for Identifying Severe Episodes and Clinical Trajectories in COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6690.	1.8	2
1436	Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma. <i>Communications Medicine</i> , 2023, 3, .	1.9	4
1437	High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. <i>PLoS ONE</i> , 2023, 18, e0283983.	1.1	7
1438	Immunology of COVID-19. , 2024, , 52-71.		0
1440	<i>Mycobacterium tuberculosis</i> and SARS-CoV-2 co-infections: The knowns and unknowns. <i>IScience</i> , 2023, 26, 106629.	1.9	3
1441	Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and $\gamma\delta$ T cell perturbations. <i>JCI Insight</i> , 2023, 8, .	2.3	4
1442	iIL13Pred: improved prediction of IL-13 inducing peptides using popular machine learning classifiers. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	0

#	ARTICLE	IF	CITATIONS
1443	Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	3
1444	Immunological Facet and Inception after Post-COVID-19 Vaccination. <i>Infectious Disorders - Drug Targets</i> , 2023, 23, .	0.4	0
1445	Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1446	Extracorporeal Membrane Oxygenation Impacts Host Transcriptomic Response in Severe Coronavirus. , 2023, , .		0
1447	Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. <i>Advances in Therapy</i> , 2023, 40, 2626-2692.	1.3	8
1448	Changes in the State of Vital Systems with Long COVID-19. <i>Biology Bulletin Reviews</i> , 2023, 13, 112-123.	0.3	0
1449	Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1450	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1451	Understanding COVID-19-related myocarditis: pathophysiology, diagnosis, and treatment strategies. <i>Cardiology Plus</i> , 0, Publish Ahead of Print, .	0.2	1
1452	Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1453	Role of Pineapple and its Bioactive Compound Bromelain in COVID 19. <i>Current Nutrition and Food Science</i> , 2024, 20, 305-316.	0.3	0
1454	Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients's susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. <i>Inflammopharmacology</i> , 2023, 31, 1029-1052.	1.9	4
1455	Cellular and Molecular Atlas of Peripheral Blood Mononuclear Cells from a Pregnant Woman After Recovery from COVID-19. <i>Maternal-Fetal Medicine</i> , 2023, 5, 88-96.	0.4	0
1456	Identification of Distinct Clinical Phenotypes of Critically Ill COVID-19 Patients: Results from a Cohort Observational Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 3035.	1.0	0
1457	Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1504	Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis. <i>Infection</i> , 0, , .	2.3	2
1524	CD34 Protein: Its expression and function in inflammation. <i>Cell and Tissue Research</i> , 0, , .	1.5	2
1541	COVID-19 (novel SARS-CoV-2) neurological illness. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 159-179.	1.0	2

#	ARTICLE	IF	CITATIONS
1552	Cancer management during the COVID-19 world pandemic. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1593	Effects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 75-110.	0.7	0
1608	T cell responses to SARS-COV-2. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , .	0.9	0
1623	Î³Î± T cells: origin and fate, subsets, diseases and immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7
1647	Correlation of the TNF-Î± SNP with infection severity of COVID-19 patients. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1672	Molecular Mimicry Study Between Peptides of SARS-CoV-2 and Neutrophil Extracellular Traps-Related Proteins. , 2024, , 43-60.		0
1681	Pharmacotherapeutics for cytokine storm in COVID-19. , 2024, , 101-125.		0
1683	Perspectives on Molecular Mimicry Between Human, SARS-CoV-2, and Plasmodium Species Through a Probabilistic and Evolutionary Insight. , 2024, , 27-42.		0
1684	Metabolic syndrome and COVID-19: AnÂunholy alliance. , 2024, , 543-554.		0
1691	Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives. <i>World Journal of Pediatrics</i> , 0, , .	0.8	0